


**MICROBIOME ANALYSIS OF WHOLE SALIVA  
USING NEXT GENERATION SEQUENCING  
TECHNOLOGY IN IMPLANT SUPPORTED  
PROSTHESIS 6 MONTHS POST LOADING**

*Dissertation submitted to*

**THE TAMILNADU DR. M.G.R. MEDICAL UNIVERSITY**

*In partial fulfillment for the Degree of*

**MASTER OF DENTAL SURGERY**



**BRANCH II  
PERIODONTOLOGY**

**MAY 2019**



**THE TAMILNADU Dr. M.G.R MEDICAL UNIVERSITY  
CHENNAI**

**DECLARATION BY THE CANDIDATE**

I hereby declare that this dissertation titled,

**“MICROBIOME ANALYSIS OF WHOLE SALIVA USING  
NEXT GENERATION SEQUENCING TECHNOLOGY IN  
IMPLANT SUPPORTED PROSTHESIS 6 MONTHS POST  
LOADING”** is a bonafide and genuine research work carried out  
by me under the guidance of **Dr. B. SHIVAKUMAR, M.D.S.,**  
Professor, Department of Periodontology, Ragas Dental College  
and Hospital, Chennai.



**Dr. Asha Srikanth**

Post Graduate Student

Department of Periodontology

Ragas Dental College & Hospital,  
Chennai.

Date: 9/2/2019

Place: Chennai



# CERTIFICATE

This is to certify that this dissertation titled "MICROBIOME ANALYSIS OF WHOLE SALIVA USING NEXT GENERATION SEQUENCING TECHNOLOGY IN IMPLANT SUPPORTED PROSTHESIS 6 MONTHS POST LOADING" is a bonafide record of work done by **Dr. Asha Srikanth** under my guidance during the study period 2016-2019.

This dissertation is submitted to **THE TAMILNADU Dr.MGR MEDICAL UNIVERSITY** in partial fulfilment for the degree of **MASTER OF DENTAL SURGERY, BRANCH II- PERIODONTOLOGY**. It has not been submitted (partial or full) for the award of any other degree or diploma.

**Guide:**



**Dr. B. Shivakumar, M.D.S.,**  
Professor,  
Department of Periodontology,  
Ragas Dental College & Hospital,  
Chennai.

**Head of the Department:**

**Dr. K. V. Arun, M.D.S.,**  
Professor,  
Department of Periodontology,  
Ragas Dental College & Hospital  
Chennai.

Department of Periodontics,  
Ragas Dental College & Hospital,  
# 2/102, ECR, Chennai - 119

**Dr. K. V. ARUN M.D.S.**  
Head of the Department  
Department of Periodontics  
Ragas Dental College and Hospital  
Chennai - 600 119.

09/02/2019

**Dr. N. S. Azhagarasan M.D.S.,**

Principal,  
Ragas Dental College & Hospital,  
Chennai.

**PRINCIPAL**  
**RAGAS DENTAL COLLEGE AND HOSPITAL**  
**UTHANDI, CHENNAI - 600 119.**

Department of Periodontics,  
Ragas Dental College & Hospital,  
# 2/102, ECR, Chennai - 119



# THE TAMILNADU Dr. MGR MEDICAL UNIVERSITY

CHENNAI

## PLAGIARISM CERTIFICATE


This is to certify that this is the dissertation work titled "MICROBIOME ANALYSIS OF WHOLE SALIVA USING NEXT GENERATION SEQUENCING TECHNOLOGY IN IMPLANT SUPPORTED PROSTHESIS 6 MONTHS POST LOADING" of the candidate DR. ASHA SRIKANTH for the award of MASTER OF DENTAL SURGERY in the branch of PERIODONTOLOGY.

On verification with the urkund.com website for the purpose of plagiarism check, the uploaded thesis file contains from introduction to conclusion, 6 percentage of plagiarism as per the report generated.

Date: 9/2/2019

Guide & Supervisor sign with Seal.

Place: Chennai.




Dr. Asha Srikanth

Post Graduate Student

Department of Periodontology

Ragas Dental College & Hospital,

Chennai



Dr. B. Shivakumar, M.D.S.,

Professor,

Department of Periodontology

Ragas Dental College & Hospital

Chennai

Department of Periodontics,  
Ragas Dental College & Hospital  
# 2/102, ECR, Chennai - 119

# *Acknowledgment*

---

---

## **ACKNOWLEDGEMENT**

*I would like to take this opportunity to express my gratitude to,*

***Dr. N.S. Azhagarasan, MDS the Principal of Ragas Dental College and Hospital, for his support and guidance during my postgraduate course at Ragas Dental College and Hospital.***

*I express gratefulness to Professor **Dr. K.V. Arun, MDS, Professor and Head of the Department** of Periodontics, Ragas Dental College Chennai, for his guidance and encouragement during my postgraduate course. I thank him for his patience and am immensely thankful for all the knowledge he has imparted during my years of study.*

*I express sincere gratitude for my guide **Dr. B. Shivakumar MDS, Professor, Department of Periodontics, Ragas Dental College and Hospital** for guiding me through the strenuous path of my dissertation and providing me with his valuable advice, guidance, support and encouragement during the entire period of my postgraduation.*

*I also extend my gratitude to **Dr. G. Sivaram, MDS, Professor, Dr. Ramya Arun, MDS, Reader**, for their continuous guidance and constant encouragement throughout my study period.*

*I would like to express my profound sense of gratitude to **Dr. Swarna Alamelu, MDS, Reader** and **Dr. Archana Meenakshi, MDS, Reader** for their constant support and encouragement throughout my tenure.*

*I would like to thank **Dr. Deepavalli MDS, Senior Lecturer, Dr. Shreemogana, MDS, Senior Lecturer** for their continuous support, timely*

*advice and guidance. I would also like to thank **Dr. A.R. Akbar, MDS, Senior Lecture, Dr. R.S. Pavithra, MDS, Senior Lecturer, Dr. J. Velkumar, MDS, Senior Lecturer,***

*I will forever remain grateful to my seniors **Dr.Arvinth, MDS, Dr.Anisha Jason,MDS, Dr. Keerthiha, MDS** and my batch mates **Dr. Ali Firouzi, Dr. Ennet Cynthia Johns, Dr. Kavi Priya, Dr. Kirupa, Dr. Santhosh Kumar** for their constant support and encouragement. I thank my juniors, especially **Dr. Lakshmi Prasanna** for her help, support and encouragement.*

*I extend my gratitude to **Mrs. Parvathi, Mrs. Rosamma, Mr. Chellapan, Mrs. Mala and Ms. Sheela** for their timely help during the tenure.*

*I would like to thank **Dr. Srinivasan H Rao M.D.S., Dr. Zeenath B.D.S.** for always being a source of inspiration and motivation.*

*I would like to thank **Mr. Mythreya**, for helping me with the statistical part of this dissertation.*

*I would like to thank my parents **Mr. Srikanth Shastri and Mrs. Geetha Shastri** and my older brother **Mr. Srinivaas Shastri** for their love, understanding, support and encouragement throughout these years. I would also like to give all my love and gratitude to my grandparents **Mrs. Padma Jayaraman and Mr. Jayaraman Iyer** who showered me with their love and prayers ever since I started my studies, without their unconditional love and understanding I would not have been at the place where I am today.*

*I would also like to express my heartfelt love and gratitude to **Mr. Ashish Jha** who was initially a close friend but became family over the years, he continued to stay by my side even when I was difficult to deal with, giving me tough love when I wanted to give up and supported me throughout the dissertation process always motivating me with every step I take.*

*I would also like to take this opportunity to thank my close friends, **Dr. Anisha Sharon Jacob, Ms.Akshaya Chandrasekaran** and **Mrs. Athira Vikram** for putting up with me even when I gave them a hard time and for constantly supporting me emotionally and not giving up on me throughout my postgraduation years.*

*My acknowledgement would be incomplete if I didn't thank the "**Creator**", the Divine Almighty who is the source of every single thought I have and who is my guiding light during difficult times.*



## LIST OF ABBREVIATIONS

ABBREVIATION	EXPANSION
PSD	<ul style="list-style-type: none"><li>Polymicrobial Synergy and Dysbiosis</li></ul>
DNA	<ul style="list-style-type: none"><li>Deoxyribonucleic acid</li></ul>
Rrna	<ul style="list-style-type: none"><li>Ribosomal Ribonucleic acid</li></ul>
HOMIM	<ul style="list-style-type: none"><li>Human Oral Microbiome Identification Microarray</li></ul>
NGS	<ul style="list-style-type: none"><li>Next Generation Sequencing</li></ul>
MSR	<ul style="list-style-type: none"><li>MiSeq Reporter software</li></ul>
HOMD	<ul style="list-style-type: none"><li>Human Oral Microbiome Database</li></ul>
HOMI	<ul style="list-style-type: none"><li>Human Oral Microbiome Index</li></ul>
OUT	<ul style="list-style-type: none"><li>Operational Taxonomic Unit</li></ul>
PCR	<ul style="list-style-type: none"><li>Polymerase Chain Reaction</li></ul>
SoLiD	<ul style="list-style-type: none"><li>Supported Oligonucleotide Ligation and Detection</li></ul>
BLAST	<ul style="list-style-type: none"><li>Basic Local Alignment Search Tool</li></ul>
MiSeq	<ul style="list-style-type: none"><li>Metagenomic Sequence</li></ul>

## CONTENTS

S.No	TITLE	PAGE NO.
1.	INTRODUCTION	1
2.	AIMS AND OBJECTIVES	6
3.	REVIEW OF LITERATURE	7
4.	MATERIALS & METHODS	44
5.	RESULTS	51
6.	DISCUSSION	57
7.	SUMMARY & CONCLUSION	67
8.	BIBLIOGRAPHY	68
9.	ANNEXURE	-



## LIST OF TABLES

TABLE NO.	TITLE
1	Distribution of bacteria in healthy and implant sites
2	Top 5 phyla in health and implant sites
3	Top 20 genera in health and implant sites
4	Top 20 species in health and implant sites
5	Periodontal health associated microbiome
6	Implant site associated microbiome

## LIST OF GRAPHS

GRAPH NO.	TITLE
1-A	Bar graph demonstrating distribution of bacterial phylum in health and implant
1-B	Bar graph demonstrating distribution of bacterial genus in health and implant
1-C	Bar graph demonstrating distribution of bacterial species in health and implant
2-A	Pie chart depicting top 5 phyla in health
2-B	Pie chart depicting top 5 phyla in gingival recession
3-A	Pie chart depicting top 5 genera in health
3-B	Pie chart depicting top 5 genera in recession
3-C	Phylogenetic tree at genus level

## LIST OF FIGURES

FIGURE NO.	TITLE
1	Bacterial Complexes
2	Roche 454 Life Sciences System
3	Illumina Solexa Genome Analyzer



# *Introduction*

---

---

## INTRODUCTION

The human body is estimated to be composed of more than  $10^{14}$  cells of which only 10% of the entire composition is of mammalian origin. Microorganisms form the major composition of cells that are found in our body, forming a resident microflora, surviving via a symbiotic relationship with the host and thus maintaining homeostasis<sup>7</sup>.

The oral cavity of the human body contains a number of different habitats, including the gingival sulcus, teeth, tongue, cheeks, hard and soft palates, and tonsils, which are colonized by bacteria. The oral microbiome is comprised of over 600 prevalent taxa at the species level, with distinct subsets predominating at different habitats, this was stated by **Floyd E. Dewhirst**. It displays the largest core of commonly related microbes among unrelated subjects when compared to the microflora found in the gut or on our skin. The relationship between periodontal microflora and the host is known to be benign, but changes in the salivary microbiome and bacterial community structures can tilt the scales and cause a disruption in the symbiotic relationship, thereby leading to the pathogenesis of periodontal disease.



Microbial shift, more commonly known as **dysbiosis**, refers to the concept that some diseases are due to a decrease in the number of beneficial symbionts and an increase in the number of pathogens<sup>20</sup>. The long-standing paradigm is that, as periodontitis develops, the oral microbiota shifts from one consisting primarily of gram-positive aerobes to one consisting primarily of gram-negative anaerobes<sup>94</sup>.

Research over the past decade has led to recognition of microbes residing in various oral ecological niches as a part of dental plaque. Plaque biofilm is a highly organized accumulation of microbial communities adhering to favourable environmental surfaces, which functions to maximize energy, spatial arrangements, communication, and continuity of bacterial communities<sup>38</sup>. The origin, development and structural adaptation of dental plaque is governed by a dynamic, ever-changing equilibrium between oral microbiota and multiple factors that differentially promote or inhibit survival of its microbial constituents.

Based on the earlier studies conducted by **Socransky et al**<sup>83</sup>, the key bacterial species which play a role in the disease process have been segregated into microbial complexes based on their correlation with clinical parameters and severity of periodontal disease.

Currently, the pathogenesis of periodontal diseases is explained by “**Polymicrobial Synergy and Dysbiosis (PSD) Model**” proposed by **Hajishengallis et al**<sup>20</sup>. This model states that dysbiotic

environment and polymicrobial synergy are the key events that led to development of periodontitis rather than individual bacterial species.

Technological research led to advancements in DNA sequencing and bioinformatics tools which later led to the development of the Omics technologies. It was observed that every individual has a specific microbiome and a metagenome that is unique and specific to that person. The development of 16s rRNA and subsequently the Next Generation Sequencing technologies led to further characterization of the microbiome<sup>57</sup>

Human Oral Microbiome Database (HOMD) is software that currently lists the entire set of organisms present in the oral cavity as a whole. Several ecological niches have been identified within the oral cavity, each with its very own distinct microbiome<sup>17</sup>.

Sampling fluids from the oral cavity, instead of other bodily fluids like blood or urine, provides an accessible medium in which a range of candidate biomarkers, such as electrolytes, proteins, antibodies, hormones and DNA/RNA, as well as other substances such as therapeutic drugs can be detected. While oral fluid assessment has been suggested to be useful in screening for or diagnosing oral or systemic diseases, monitoring viral or fungal infections, there is a lack when it comes to detecting drug exposure, and evaluating endocrine

disorders and cancer risk, evidence of utility for most of these purposes is lacking.

There continues to be interest in oral fluid as a diagnostic medium for rapid, point-of-care testing. Potential advantages of using saliva for disease diagnostics include the sample collection in toto being an easy and noninvasive procedure which thereby increases patient compliance, and there is a decrease in the risk of infectious disease transmission. Readily accessible fluids include: whole saliva, secretions from specific glands, mucosal transudate, or gingival crevicular fluid. Although various methods of collecting saliva and other oral fluids affect the precision and determination of biomarkers of interest, to date, there are no established uniform criteria available for the collection of human saliva<sup>29, 35</sup>.

Dental implants are made of materials which are biocompatible with the host tissue, which when placed in the alveolar bone provide anchorage and support to the prosthetic superstructure that is fabricated. Peri-implant tissues are only thought to be of microbial origin and closely to parallel to periodontal diseases in the form of etiopathogenesis. However there is still some ambiguity in literature about the microflora in implants when compared to tooth.

Development of alternative methods instead of the traditional culturing methods has led to assess dental biofilms based on DNA analysis or other molecular techniques. Studies of salivary microbial community identified a link between taxonomic composition and disease pathogenesis. Current trend in sequencing of microbiome is based on Next-Generation Sequencing (NGS) that uses parallel sequencing of multiple small fragments of DNA to determine genetic sequences.

NGS technology was utilized earlier in our department (unpublished data) to identify and characterize subgingival microbiome from periodontal pockets and gingival recession.

Salivary microbial profiling may be a promising method of identifying further disease progression in both periodontitis and peri-implantitis. In this regard, the salivary microbiome in periodontal health and in healthy implant sites must first be established.

For a better understanding and in an attempt to analyze and characterise the salivary microbiome in periodontal health and in healthy implants six months post loading using Next Generation Sequencing Technology, the current study was undertaken.



# *Aim and Objectives*

## **AIM AND OBJECTIVES**

### **Aim:**

To determine salivary microbiome using NGS technology in patients with implant supported prosthesis placed (6 months post loading).

### **Objectives:**

1. To identify and characterize the salivary microbiome in patients with implant supported prosthesis placed (6 months post loading) using Next Generation Sequencing Technology.
2. To compare and analyze the salivary microbiome in sites of in patients with implant supported prosthesis placed (6 months post loading) with those of periodontally healthy controls.
3. To study species diversity in salivary microbiome, and characterize novel micro-organisms in in patients with implant supported prosthesis placed (6 months post loading).

# *Review of Literature*

---

---

## **REVIEW OF LITERATURE**

The human body is an entire living organism as a whole composed of various cells that combine together to form tissues which in turn lead to the formation of organs. Microorganisms are present all over our body and they contribute to the majority of cells that are found in our body, thereby forming the resident micro-flora and survive by having a symbiotic relationship with the host, thereby maintain homeostasis<sup>41, 73</sup>.

### ***The oral microbiome***

The human body is estimated to have  $10^{14}$  cells, out of which only 10% are of mammalian origin<sup>70</sup>. The oral microbiome is completely unique and distinctive due to its characteristic physical and biological abilities and the properties associated to each site despite the potential movement of micro-organisms between sites. They have the ability to attach to tooth surfaces or the epithelial surfaces of the gingiva and periodontal pocket. Combining these key observations led to the formulation of a core concept that illustrated the properties of the habitat are selective and dictate which organism are able to colonise, grow and whether they are minor or major members of the community<sup>25, 93</sup>.



## **The Germ Theory**

The **germ theory of disease** is the scientifically accepted current concept of disease. It states that, the main causes of many diseases are micro-organisms. These small organisms, microscopic in nature, invade the human cells, animal cells, and other living hosts. Their ability to grow and reproduce within the host cells can cause a disease. "**Germ**" doesn't just refer to bacterial origin but to any type of microorganism, especially one which causes disease, such as fungi, viruses, protozoa etc.

Microorganisms that cause diseases are classified under the term "PATHOGENS". The diseases they cause are of an infectious nature. Even when a pathogen is the principal cause of a disease, other factors like environmental and hereditary often influence the severity of the disease, and whether a potential host individual becomes infected when exposed to the pathogen.

The germ theory was proposed by **Girolamo Fracastoro**<sup>33, 43, 123</sup> in 1546, and expanded upon by **Marcus von Plenciz**<sup>82</sup> in 1762. Even though the theory was established, it was not popular among the practising doctors and scientists during the day, they still followed **Galen's** miasma theory<sup>49</sup>. The drawback of this belief in the theory prevented them from understanding how diseases actually progressed, with predictable consequences. By the early nineteenth century, smallpox vaccination was common among the practioners in Europe, though doctors were unaware of how it worked or how it's principles extended

to other diseases. Viruses were later discovered in the late 1800s sometime around 1890.

### **The Miasma theory**

The miasma theory was the most common theory of disease followed in the 19th century before the establishment of germ theory. It stated that diseases such as cholera, chlamydia infection, or the Black Death were caused by a *miasma* (Ancient Greek: "pollution"), a noxious form of "bad air" emanating from rotting organic matter. The theory posited that diseases were the product of environmental factors such as contaminated water, foul air, and poor hygienic conditions. Such infections, according to the theory, were not passed between individuals but would affect those within a locale that gave rise to such vapours.

### **Robert Koch and his Postulates**

Robert Koch is known for develop Koch's postulates that demonstrated, in a scientifically sound manner, that a disease is usually caused by a particular organism. These postulates were formulated from his work with anthrax using purified cultures of the pathogen that had been isolated from diseased animals.

Koch's postulates were developed to serve as guidelines as to which pathogens can be isolated in the treatment of a disease in the 19<sup>th</sup> century. In the 1980s, a

molecular version of Koch's postulates was developed to guide the identification of microbial genes encoding virulence factors.

**Koch's postulates:**

1. The microorganism must be found in abundance in all organisms suffering from the disease, but should not be found in healthy organisms.
2. The microorganism must be isolated from a diseased organism and grown in pure culture.
3. The cultured microorganism should cause disease when introduced into a healthy organism.
4. The microorganism must be re-isolated from the inoculated, diseased experimental host and identified as being identical to the original specific causative agent.

**Socransky's criteria**

Proposed a criteria by which periodontal microorganism can be classified as a periodontal pathogen based on checkerboard DNA technique, he later classified the different colour complexes of the bacteria based on their time of colonization<sup>83, 106, 108</sup>

- 1. Must be associated with disease**, as evident by **increase** in the **number of organisms** at diseased sites
- 2. Must be eliminated or decreased in** sites that demonstrate **clinical resolution** of disease with treatment

3. Must demonstrate a **host response**, in the form of an alteration in the host cellular or humoral immune response.
4. Must be capable of **causing disease in experimental animal model**.
5. Must demonstrate **virulence factors** responsible for enabling the microorganism to cause destruction of periodontal tissue<sup>109</sup>

### **Dental Implants**

Dental implants have become an indispensable and in vogue form of therapy in dentistry in order to replace missing teeth in different clinical situations. With success rates as high as 82,9% 16 years post loading have been reported. With careful attention to the indications, anatomical and also keeping in mind the intra-individual limiting factors, insertion of dental implants seems to represent itself as “safe” modality when it comes to the treatment option of replacing missing teeth<sup>42, 43</sup>. Nevertheless, in the last few decades increasing evidence have been raised on the presence of peri-implant inflammations<sup>55, 57</sup>. It is being represented as one of the most frequent complications affecting both the surrounding soft and hard tissues which can lead to the loss of the implant. Therefore, strategies for prevention and treatment of peri-implant disease should be integrated in modern rehabilitation concepts in dentistry<sup>50</sup>.



### **Peri-implant Tissues and Peri-implant Diseases**

The soft tissue surrounding a dental implant is termed as the peri-implant mucosa while the soft tissue surrounding a tooth is known as the gingiva. Although there are similarities between these two types of tissues, they have differences among each other present at a histological level <sup>69</sup>. The soft tissue present around an implant consists of keratinized and non-keratinized epithelium, similar to that of the periodontal tissues around the natural tooth. Unlike the natural tooth, there is an absence of the periodontal ligament between the implant and the surrounding bone, and the implant-bone contact is directly supplied, and is not done not via the fibers <sup>104</sup>.

Because the dental implants placed in the oral cavity are in direct contact with the bone, the forces applied cannot be compensated. In addition, the peri-implant tissues are devoid of mechanoreceptors in the periodontal region that which are crucial when it comes to recognize the sense of touch.

Pathological changes that occur in the tissues that surround the implant are called peri-implant diseases. If these inflammatory changes are limited only to the soft tissues, they are known as peri-implant mucositis and they are called peri-implantitis only when the disease spreads to the underlying alveolar bone<sup>2, 4</sup>. In a systematic review published by **Derks et al. in 2015** <sup>20</sup>, the prevalence of the condition called peri-implant mucositis was reported to be between 19% and 65%, and the prevalence of peri-implantitis ranged between 1% to 47%.

**Mucositis** is a term that describes a bacteria-induced, reversible inflammatory process of the peri-implant soft tissue with reddening, swelling of the soft tissue and also bleeding on periodontal probing.

In contrast to mucositis, **peri-implantitis** is a more progressive and irreversible disease of the hard and soft tissues surrounding an implant and is accompanied usually with bone resorption and decreased osseointegration along with increased pocket formation and purulence. After the insertion of titanium implants, within the peri-implant sulcus, rapid colonization of bacteria has been observed<sup>127</sup>. Some microbiological studies have shown that implants affected by peri-implantitis tend to harbour microbiota consisting of the key periodontal pathogen species, including *Porphyromonas gingivalis*, *Aggregatibacter actinomycetemcomitans*, *Tannerella forsythia*, *Prevotella intermedia*, and *Fusobacterium* species.

Clinically, typical symptoms associated to peri-implant infections are: redness, oedema and bleeding observed in the soft tissues in the peri-implant mucositis. In peri-implantitis patients, clinical findings such as an increase in probing depth values and detection of radiographic bone loss are usually added to the already present clinical symptoms<sup>14</sup>. The etiology of peri-implant diseases and the etiology of periodontal diseases are similar. However, the fact that there is no real fibrous connective tissue attachment around the implants as it is in the teeth makes the tissues around the implant makes it more sensitive to microbial attack. Bacterial infection has a very important role in the success of

dental implants. In clinical and animal studies, bacterial plaque accumulation around the implant caused inflammatory reaction in peri-implant tissues.

### **Microbial etiology of Peri-implant diseases**

Considering that the infectious nature of peri-implantitis is caused by the accumulation of a complex biofilm community on the implant surface, it seems sensible to try to map out the microbial profile of this disease. However, till date any hope of finding out what the actual cause of a peri-implant infection is still not a reality<sup>17</sup>. This has happened far earlier for periodontitis, and a lot of common lessons apply for both pathological entities. Therefore, the fundamental principle that is applicable for periodontitis can be used for peri-implantitis as well, i.e. peri-implantitis like periodontitis it is an opportunistic, endogenous, polymicrobial infection. This implies that the pathological species associated with the destructive disease are parts of the normal oral microbiota, but under certain ecological shifts (dysbiosis) become pathogens, never alone, but always acting in synchrony. It is not the mere presence of specific bacteria instigating the disease origin rather it's the interplay of divergent abundant bacteria from different phyla.

Over the years different methods have been applied to characterize the peri-implant microbiota. Culture-dependent methods have traditionally been the gold standard, but now molecular methods have been introduced to avoid conventional time-consuming laboratory work. With the new millennia, sequencing methods have started to take over the industry, including the latest

next-generation sequencing, have emerged to reveal in more detail differences between healthy and diseased oral microbiomes<sup>17</sup>.

Bacterial colonization on the implant surface starts 30 min after insertion, and similar bacterial taxa can be identified on the implant after several months. The bacterial composition of the biofilm formed and observed on implants is similar to that of the adjacent teeth<sup>30</sup>. Hence, the microbial flora found on natural teeth are actually “*a reservoir*” for the biofilms that build-up around implants. In respect to the initial (i.e. 4 weeks) subgingival colonization, the frequency of detection of different species is similar between that of natural teeth and implants. Nevertheless, the colonization pattern on implants appears to be initially slower than on natural teeth. The peri-implant microflora in health consists mainly of Gram-positive cocci and non-motile bacilli, and a limited number Gram-negative anaerobic species, resembling gingival health. Nevertheless, the switch to peri-implant mucositis is associated with an increase in the presence of cocci, motile bacilli and spirochetes, at proportions comparable to gingivitis. The transition to peri-implantitis is associated mainly with the emergence of Gram-negative, motile, and anaerobic species that are commonly found in periodontitis<sup>52, 65</sup>.

Based on clinical studies it was observed that while the three “red complex” species, namely *Porphyromonas gingivalis*, *Tannerella forsythia* and *Treponema denticola*, can be found at higher counts in peri-implantitis. Collectively, it appears that the qualitative composition of the biofilm microflora in peri-implantitis resembles that of periodontitis, this in turn



implies to the fact that patients with active periodontal disease are at higher risk for developing peri-implantitis. Submucosal biofilms obtained from peri-implantitis patients also yield bacteria that display in-vitro resistance to one or more standard antibiotic treatments. These are most often *Prevotella intermedia/nigrescens* or *Streptococcus constellatus*.

Nevertheless, a number of microorganisms have been identified in peri-implantitis patients that are not commonly observed in patients with periodontitis <sup>32</sup>. These include bacterial species such as *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Enterobacter aerogenes*, *Enterobacter cloacae*, *Escherichia coli*, *Helicobacter pylori*, *Peptostreptococcus micra*, *Pseudomonas spp*, as well as *Candida spp* fungi. Presence of *S. aureus* shortly after implant insertion can be confirmed even one year later. It has also been shown that up-to 18.6% of peri-implantitis lesions harbour aerobic Gram-negative bacilli, such as enteric rods and coliforms, or non-enteric rods, but the microbial concentration may not fully correlate to the severity of the disease.

Putative periodontal pathogens may be detected at higher levels, prevalence and numbers, than in fully edentulous patients. Early studies indicated absence of detection of *Aggregatibacter* .

**Higher roughness** and **higher free energy** of the implant surface may favour biofilm formation, whereas peri-implantitis may occur earlier, with a faster and more extensive progression in implants with rougher surface.

In this respect, potential differences in bacterial adhesion due to surface microstructure may partially be equilibrated by the mediating salivary pellicle.

Hence, given the biological involvement of the pellicle, implant surface characteristics may not notably affect the initial stages of biofilm formation and composition.

### **Peri-implant Tissue Microbiology**

Peri-implant diseases after successful osseointegration of intra-bone implants are caused by an imbalance between bacterial activity and host response. The response to inflammation in peri-implant diseases may be confined to the mucosa around the implant as it is in the peri-implant mucositis, or it may progress and cause loss of bone tissue and lead to peri-implantitis<sup>72</sup>.

Periodontal and peri-implant diseases are infections caused by microorganisms. Therefore, the use of microbiological parameters has an important role in both microbial development and routine diagnosis and follow-up. It has been reported that periodontal pathogens are detectable around dental implants that begin to function in the oral environment in a short period of a month<sup>79</sup>.

After implant placement periodontopathogens are found present in healthy microflora. **Koka et al.**<sup>36</sup> in his study observed the existence of *P. gingivalis*, *P. intermedia*, *Actinomyces naeslundii*, *F. Nucleatum* and *T. denticola* in the

plaque samples on the 14th and 28th days after opening of the implant into the oral environment was investigated in comparison with natural teeth.

According to the data that was obtained, these species can be determined after 14 days and within 28 days; a complex salivary microbiota has been reported to colonise the site . Although there are only a few changes in the microbial species profile around the tooth, there has been a significant increase in the amount of *F. nucleatum*ss *vincentii*, *Peptostreptococcus micros*, *Prevotella nigrescence* and *P. Gingivalis* species around the implant over time. The species such as *S. mitis* and *S. oralis* seen in early colonization on teeth were also colonized at the second week around the implants and maintained their levels for 26 weeks. It has been reported that in the salivary flora of clinically healthy implants, there is a high proportion of bacteria in the form of cocci, and that spirochetes, motile bacilli and Gram (-) anaerobic species are none or low. It has been reported that there is a high rate of spirochetes and motile bacteria in clinically deep pockets and implants with increased alveolar bone loss<sup>79</sup>.

Periodontopathogenic bacteria such as *porphyromonas gingivalis*, *treponama denticola*, *tannerella forsythensis* and *aggregatibacter actinomycetocomitans* have been shown to be similar in peri-implant pockets and in periodontal pockets.

**Leonhardt et al.**<sup>39, 41</sup> compared microbial flora found in the vicinity of healthy implants with the one in implants where peri-implantitis observed, they reported that in the study group 60% of the implants were detected with *P.*

*gingivalis*, *P. intermedia*, *A. actinomycetemcomitans* and *P. nigrescence* with 55% *Staphylococcus spp.*, *enteric* and *Candida spp.* and none of these microorganisms were detected in the healthy group.

Implant loss can be differentiated on the basis of the following additional factors:

- Overloading of the implant,
- Faults in material and techniques,
- Poor bone quality at the implant area,
- Systemic diseases and drug therapies, which inhibit bone modulations according to “Wolff’s law” (bone density and strength increase with stress - and vice versa).

Thus, implants of more than 10 mm length in square thread design show higher success rates than shorter implant lengths or shapes without thread or buttress thread<sup>62, 65</sup>. Also rough implant surfaces of more than 2 microns seem to feature better osseointegration than smooth (<0.5 microns) or moderate surfaces (1–2 microns)<sup>105</sup>

### **Mechanical overload in implants**

Occlusal trauma in an implant patient may be defined as an injury to apparatus used as an attachment is the result of excessive occlusal force directed to the apparatus. There is a current controversy regarding the role of occlusion in respect to the amount of bone loss observed after the delivery of an implant prosthesis<sup>112</sup>.

There is generalized consensus that was made in respect to the fact that early implant failure may be associated with overload. However, some articles conclude that peri-implant bone loss without implant failure is primarily associated with biological formations or complications <sup>1,48</sup>.

Other authors suggest a correlation of crestal bone loss to occlusal overload.

The relationship between “*stress and strain*” determines the modulus of elasticity (stiffness) of a material <sup>67</sup>. Hence, the modulus refers to the amount of dimensional changes that occur in a material for the given amount stress level. The *modulus of elasticity* of a tooth is similar to that of cortical bone. Dental implants are usually fabricated using titanium or its alloy. The modulus of elasticity of titanium is 5 to 10 times greater than that of cortical bone <sup>5,8</sup>.

An engineering principle known as “*the composite beam analysis*” states that when two materials of different elastic moduli are placed together with no intervening material, of which one is loaded, a stress contour increase will be observed where the two materials first come into contact.

In the oral cavity when it comes to an implant-bone interface these said stress contours are of greater magnitude at the bone’s crestal region <sup>90</sup>. This phenomenon was observed in both photo-elastic and also a 3-dimensional finite element analysis studies when implants were loaded within a bone simulant.

### **Bone Mechanical Properties**

The density of bone is said to be directly related to the strength and elastic modulus of bone. Hence, in bone with higher density the amount of strain is lesser and experiences a lesser load when compared to softer bone <sup>68</sup>. As a result, the amount of remodeling in denser bone is lesser compared to softer bone when they experience similar load conditions <sup>3</sup>.

A decrease in the amount bone remodeling can result in lower levels of bone loss. In a prospective human study, **Manz** observed that the amount of marginal bone loss observed next to an implant was directly related to the density of the bone.

**Hoshaw et al** conducted a study in dogs where loaded threaded implants were placed in the oral cavity of the canines with a tensile load and he noted that the fine trabecular bone pattern became coarse trabecular bone around the implant <sup>98</sup>. Fine trabecular bone is less dense when compared to coarse trabecular bone. Since the density of bone is directly related to its strength and elastic modulus, the crestal bone strength and biomechanical mismatch between titanium and bone may improve in relation to the functional loading. In other words, the stresses applied to the peri-implant bone may be great enough to cause bone resorption during the first year, since bone strains are greatest at the crest. But the stress applied below the crest of bone is of less magnitude and may correspond to the physiologic strain, which allows the bone to gain density and strength <sup>103</sup>. As a result, the occlusal load that causes bone loss initially (overload), is not great enough to cause continued bone loss once the bone matures and becomes more dense.



### **Implant Design Biomechanics**

Implant design may change the amount or type of forces applied to the bone-implant interface<sup>118</sup>. A smooth collar at the crest module may transmit shear forces to the bone. Bone is observed to be strongest under compressive forces, 30% weaker under tensile loads, and 65% weaker to shear forces.

Bone may heal to the smooth metal collar of the implant crest module from implant insertion to implant exposure; but when under loading conditions, the weaker shear interface may be more inclined to overload the bone. The first thread of the implant is where the type of force changes from primarily shears to compressive and/or tensile loads.

Therefore, in many situations the 35 to 65% increase in bone strength through changes from shear to compressive loads is sufficient to halt the bone loss process. This may be one of the reasons why implant designs with a 2 mm smooth collar above the first thread and a 4 mm smooth collar above the first thread, both lose bone to this “first thread” landmark<sup>12, 113</sup>.

### **Factors of the implant affecting adhesion of bacteria on its surface**

#### **Surface roughness**

Broad and detailed research shows that both the amount of plaque formation and the maturity of the plaque, with increasing numbers of motile rods,

increase in proportion to the roughness of the surface. Several studies have investigated roughness and bacterial adhesion by altering a titanium surface.

According to a study conducted by **Amoroso et al**, the adhesion of *Porphyromonas gingivalis*, as a cause of periodontal disease, significantly declined on a “very smooth” titanium surface, i.e., much smoother than the one commonly used as an implant abutment ( $Ra = 34.57$  vs.  $350$  nm, respectively) <sup>6,119</sup>.

The dependence of bacterial adhesion on titanium surface roughness was confirmed in a recent *in vitro* study.

Among three titanium disc surfaces, an acid-etched and blasted surface showed significantly higher roughness and proportionately higher adhesion by *Streptococcus mutans*, *Porphyromonas gingivalis*, and *Fusobacterium nucleatum* than either a machined or acid-etched surface.

A recent study using an *in vivo* model evaluated the effects of titanium surface roughness on initial bacterial adhesion by *Streptococcus sanguinis*, *Actinomyces naeslundii*, and *Lactobacillus salivarius*. The rougher blasted surface, with a  $Sa$  of about  $1.5\text{ }\mu\text{m}$ , showed greater bacterial adhesion than the turned surface, with an  $Sa$  of  $0.18\text{ }\mu\text{m}$ . An anodically oxidized surface ( $Sa = 0.4\text{ }\mu\text{m}$ ) also promoted greater microbial attachment than the turned surface. The augmented resistance of the rougher surfaces to shear forces was suggested to cause the increased bacterial adhesion <sup>122, 135</sup>.

While bacterial adhesion declines as surface roughness decreases, there is a lower limit to this relationship, at a roughness called the “**threshold  $Ra$** .” **Bollen et al** reported that there was no effect on the salivary microorganism

composition in the short-term or in the long-term when the Ra was  $< 0.2 \mu\text{m}$ . In that study, the authors connected the titanium abutment (Ra =  $0.2 \mu\text{m}$ ) to the fixture and sufficiently grounded the ceramic abutment (Ra =  $0.06 \mu\text{m}$ ) also to the fixture. After intraoral exposure of these setups for 3 and 12 months, the clinical periodontal index and plaque samples were compared. Both the number and the composition of the pathogenic bacteria were found to depend on the roughness of the abutments, with an increase in probing depth and greater bleeding in response to probing determined on rougher versus the smoothest abutments<sup>7</sup>.

This result correlated with the results of an *in-vivo* study by **Quirynen et al**<sup>28</sup>, who monitored the clinical and microbiological findings obtained with four grounded titanium abutments, with Ra values  $\leq 0.2 \mu\text{m}$ , for 3 months. While spirochetes were observed only around the roughest of abutments, there were no other differences observed in salivary microbial population, providing further evidence of a said threshold level below which reduced bacterial adhesion doesn't confer a clinical benefit<sup>13</sup>. Also, the results of this study showed that although some attachment gain (0.2 mm) was achieved in the roughest abutment, the other abutments had at least a minimum of 0.8 mm of attachment loss, indicating that a certain degree of roughness of surface is needed for providing a resistance against probing.

#### **Surface free energy (SFE)**

The technique called **sessile drop** is frequently used to determine the energy of solid surfaces. It involves the measurement of the contact angle between a droplet of liquid with a known surface energy and the solid surface of interest.

Because roughness is one of the several factors affecting the contact angle, roughness itself will affect the surface free energy (SFE).

**Busscher et al** reported the surface roughness's effects on the contact angle disappeared when  $R_a$  was  $< 0.1 \mu\text{m}$ . Thus, while the SFE is independent of roughness below certain values of  $R_a$ , further experiments must be conducted to interpret this finding.

Recent *in vitro* research has evaluated SFE and bacterial adhesion using disc samples whose surfaces consisted of a polished, partially stabilized zirconia material, (titanium blasted with zirconia, titanium blasted with zirconia, and then acidetched, or polished titanium). The surfaces of polished partially-stabilized zirconia and titanium blasted with zirconia were found to have a lower SFE and decreased bacterial adhesion property (*Streptococcus mitis* and *Prevotella nigrescens*). The authors concluded that SFE is the most important factor determining initial bacterial adhesion.

Bacterial adhesion was shown to correlate with the total SFE and the proportion of the nonpolar component of the material. These findings correlated with those of **Pereni et al**<sup>73, 133</sup>, in which an association between SFE and bacterial retention was demonstrated, albeit using other bacterial species.

The SFE of the substratum is related to the SFE of the bacterial clusters. On low-SFE surfaces, bacterial clusters with lower SFEs were shown to be predominant. In addition to the SFE of the substrate and of that of the bacteria, that of the suspending medium is also important. In addition, the pellicle

coating was shown to have homogenizing effects on the SFE, indicating the complexity of SFE effects even under defined conditions.

## **MATERIALS**

Titanium is commonly used as the abutment material because of its superior biocompatibility. Recently, however, zirconia has been increasingly preferred for esthetic reasons; thus, many studies have compared zirconia and titanium. The results of a study conducted by **Scarano et al** supported the use of zirconia. In that *in vivo* human study, an intraoral device adhered with either zirconia or titanium disc samples was exposed for 24 hours, after which the surface was analyzed with SEM to measure the rate of bacterial covering<sup>20, 59</sup>. Significantly less adhesion was observed with zirconia (12.1%) than with titanium (19.3%), indicating the appropriateness of the former as an abutment material.

Nonetheless, many researchers reported no differences between the two materials. **Rasperini et al** conducted a study in which a microbiological analysis of samples collected from titanium and zirconia abutments at 6 hours, 24 hours, 7 days, and 14 days were done<sup>60,126</sup>. Maximum colonization occurred after 24 hours of intraoral exposure and was maintained consistently until the 14th day, with no differences between the two materials. A similar study conducted by **Brakel et al** prolonged the observation period. Bacterial

composition and soft-tissue health at the second post-operative week and third post-operative month were not significantly different in the zirconia versus the titanium group. In an *in-vitro* study comparing pellicle composition and bacterial binding properties, zirconia and titanium yielded similar results that were significantly different from those obtained with hydroxyapatite<sup>76</sup>.

A recent *in vivo* study compared dental ceramics with respect to biofilm formation. Glass ceramic, lithium disilicate glass ceramic, yttrium-stabilized zirconia (Y-TZP), pressed Y-TZP ceramic, and a pressed mixed ceramic with Y-TZP and 25% alumina, all with similar surface roughness (mean Ra = 0.04 µm), were tested. Plaque accumulation was lowest in the pressed Y-TZP ceramic and highest in the lithium disilicate glass-ceramic, suggesting that the material itself also has an effect on biofilm formation, although this is partly related to its surface energy<sup>51, 133</sup>. The use of a gold alloy as an abutment material analogous to the use of zirconia and titanium has been examined in several animal and clinical studies aimed at estimating its biological reliability by measuring the periodontal index and assessing soft-tissue stability.

### **Salivary diagnostics**

Saliva and other oral fluids (for example: oral mucosal cellular secretions, and gingival crevicular fluid) support the health of the soft and hard tissues present in the oral cavity. The protective functions of saliva mainly include maintaining a neutral oral pH, cleaning and re-mineralizing teeth, facilitating



swallowing and digestion, and protecting oral tissue against desiccation and invasion by micro-organisms<sup>76, 86</sup>.

Adequate saliva is essential for maintaining oral health, and reduced salivary secretion (i.e., hyposalivation) or xerostomia (i.e., dry mouth) can contribute to oral problems such as dental-caries, periodontal diseases,etc <sup>10</sup>. There continues to be interest in oral fluid as a diagnostic medium for rapid, point-of-care testing. Potential advantages of using saliva for disease diagnostics include ease of access, noninvasive sample collection, increased acceptance by patients, and reduced risks of infectious disease transmission. Readily accessible fluids include whole saliva, secretions from specific glands, mucosal transudate, or gingival crevicular fluid<sup>36, 39</sup>.

Although various methods of collecting saliva and other oral fluids affect the precision and determination of biomarkers of interest, to date, there are no established uniform criteria for collection of human saliva<sup>19, 67</sup>. Currently, oral fluid testing by clinical laboratories is regulated under the Clinical Laboratory Improvement Amendments of 1988 (CLIA).

**Oral Fluid Bio-components**

Bio-component Class	Examples
Hormones	Cortisol, androgens, estriol, estrogen, progesterone,

	aldosterone, melatonin, insulin
Cytokines	Interleukins (IL-1beta, IL-6, IL-8), tumor necrosis factor, troponin
Antibodies	IgG, IgA
Proteins/Enzymes	Amylase, pepsin, matrix metalloproteinases, C-reactive protein (CRP), mucins, lactoferrin, antimicrobial peptides
Growth Factors	Epidermal growth factor (EGF), vascular endothelial growth factor (VEGF) insulin-like growth factor
Nucleic Acids	Human and microbial DNA, mRNA, microRNA, tRNA-derived small RNA (sRNA)
Viruses	HIV, HSV-1, HSV-2, EBV, HPV, CMV, VZV, HCV
Bacteria	<i>P. gingivalis</i> , <i>S. mutans</i> , <i>Lactobacillus</i> spp, <i>T. forsythia</i> , <i>E. coli</i> , <i>H. pylori</i> , <i>M. tuberculosis</i>
Fungi	<i>Candida</i> , <i>Aspergillus</i>
Drugs	Anticonvulsants, chemotherapeutic agents (including antibiotics and antineoplastic agents), analgesics, drugs of abuse, ethanol
Metabolites/Electrolytes	Phosphate, calcium, sodium, potassium, glucose, chloride, nitrate, uric acid, amino acids, lipids, carbohydrates

Tumour Markers	CA 15-3, HER2/neu, CA 19-9, p53, leptin, CA 125, alpha fetoprotein, CEA, somatic mutations in tumor suppressor genes, loss of heterozygosity, promoter hypermethylation of genes, microsatellite DNA alterations
----------------	--

**Peri-implant sulcular fluid (PISF)**

The current criteria used in the diagnosis of periodontal conditions clinically, has created a limitation in the utility to predict disease progression in the future <sup>20</sup>. The potential role of host response and microbial biomarkers obtained from oral fluids have been investigated and based on these investigations they are being used as complementary diagnostic tools for periodontal disease. Concentrations of host response molecules maybe used as a representation for a more accurate measurement of real-time disease activity than conventional clinical measurements <sup>28,37</sup>

Microbial communities from subgingival and supragingival biofilm have been clustered in complexes according by their relationship to commonly used clinical parameters <sup>83,105</sup>.

The red complex bacteria (*Porphyromonas gingivalis*, *Tannerella forsythia*, and *Treponema denticola*) and orange complex member (*Prevotella intermedia*) have been pointed out as the species responsible for chronic periodontitis <sup>37</sup>, while *Aggregatibacter actinomycetemcomitans* for aggressive

periodontitis <sup>47</sup>. Furthermore, besides being highly associated with disease, assessments of microbiological presence and load are able to predict its progression in susceptible sites <sup>9, 53</sup>. The pairing of both data has been proven valuable to increase their diagnostic abilities in crosssectional and longitudinal models in subjects afflicted with periodontitis <sup>36, 54</sup>. Conversely, limited information regarding the usefulness of biomarkers upon peri-implantitis is available.

Radiographic and clinical assessments such as radiographic bone loss evaluation, peri-implant probing, bleeding on probing (BOP), microbial testing, implant mobility, and suppuration all serve as traditional measuring tools for peri-implant surveillance and disease diagnosis <sup>86</sup>. Moreover, an increasing interest for the assessment of numerous inflammatory mediators, host proteolytic enzymes and tissue breakdown biomarkers, in addition to angiogenic and matrix metalloproteinase inhibitors biomarkers within gingival crevicular fluid (GCF) and peri-implant crevicular fluid (PICF) has been targeted for disease detection and prediction to elucidate a broad overview of the different phases of the periodontal and peri-implant diseases <sup>87, 132</sup>

Identifying a single predictive biomarker for periodontal and peri-implant diseases would be of great significance. However, microbial profiles and a combination of several host response biomarkers around dental implants could reveal a more precise assessment of a disease status than traditional clinical measurements as observed in a periodontitis model <sup>35, 36</sup>

### **Factors that correlate with marginal bone loss in implants**

A positive correlation has been found between oral hygiene and marginal bone loss around implants in the edentulous mandible <sup>48</sup>. During peri-implant breakdown a complex microbiota is established, closely resembling that found in adult periodontitis <sup>31, 77</sup>. When peri-implant tissue breakdown is induced by placing plaque retentive ligatures submarginally, a shift in the microflora occurs <sup>64, 65</sup>. Apart from darkpigmented Gram-negative anaerobic rods, other bacterial species associated with per-implant infection include *Bacteroides forsythus*, *Fusobacterium nucleatum*, *Camphylobacter*, *Peptostreptococcus micros*, and *Streptococcus intermedius* <sup>58</sup>. Organisms not primarily associated with periodontitis, such as *Staphylococcus* spp., Enterics and *Candida* spp. have also been found in peri-implant infection) <sup>87</sup>.

#### **Association of peri-implant disease with periodontal disease**

Studies have shown that the microbiome that is found around implants that have failed are similar to that found around the teeth affected with periodontitis in their composition as well as their proportion of microorganisms <sup>100,116</sup>. Hence, the association of peri-implant disease with periodontal disease have been reported for several studies.

The incidence of the condition peri-implantitis has increased continuously over the last few years, ultimately relating it with the loss of implants. Many factors play a fundamental role in creating complications that are related to implant failures like the implant and prosthetic component's design as well as bacterial colonization around implants <sup>4</sup>. The colonization of bacteria around dental implants can lead to some local diseases, the most common being:

mucositis and peri-implantitis. These two forms of infections resemble gingivitis and periodontitis respectively.

Based on a study conducted by **Renvert & Persson**, showed that patients with a previous history of periodontitis have been proven to have an increased risk of acquiring peri-implant infections. Another study conducted by **Heitz-Mayfield & Lang** <sup>64</sup>, concluded that patients who are susceptible to periodontal disease, are seen to possess a higher susceptibility to peri-implant disease when compared to those patients without any history of periodontal disease. To decrease the chances of implant loss due to the presence of periodontopathogenic bacteria, several researchers have proposed the elimination of these pathogens before dental implant installation.

Although, the microbiological profile at failing implants differs from those in peri-implant health, it is not known whether the host response observed in peri-implantitis patients is similar to that seen in periodontitis <sup>117</sup>.

Since a great number of patients receiving dental implants are patients with a history of periodontal disease, i.e. individuals who previously have shown a tissue destructive inflammatory response, a microbial challenge in conjunction with an aberrant host response are possible etiologic factors.

Analysis of inflammatory mediators in crevicular fluid has also been used to compare peri-implant tissue health and disease. Neutrophil- derived enzymes such as neutral protease, neutrophil elastase, myeloperoxidase and b-glucuronidase have been found in association with failing implant sites <sup>11</sup>. Interleukin-1 (IL-1) is a potent proinflammatory cytokine that can influence the host response in the inflammatory tissue destruction. IL-1 is produced



mainly by macrophages but also by other cells including neutrophilic granulocytes<sup>92</sup>.

Peri-implantitis may have a multifactorial background where an aberrant host response in conjunction with the bacterial challenge may contribute to the development of tissue destruction around implants. Elucidation of factors of importance for peri-implant tissue destruction should make it easier to predict which patient or implant is at risk for peri-implant complications during maintenance and retention of implants. In the present study, we therefore aimed to characterise markers of inflammation, microbiota and inflammatory host response at implants and teeth in patients with signs of marginal tissue destruction, i.e. peri-implantitis<sup>107,110</sup>

### **Salivary diagnostics and implant patients**

The current world of research is probing the different facets involved in periodontal disease diagnostics and is currently investigating the possible use of oral fluids, such as saliva, for disease assessment. The secretions obtained from the major salivary glands (parotid, submandibular and sublingual), which usually consist of a large number of proteins and peptides, are responsible for maintaining the integrity of the oral cavity<sup>101, 121</sup>. Also, because of its importance in oral biofilm formation and host defense, secreted saliva may play a significant role in the establishment and progression of periodontal disease.

Saliva an oral fluid is considered to be a mirror of the body. It could be used to monitor the general health and also the onset of specific diseases. Biomarkers, whether produced by normal healthy individuals or by individuals affected by specific systemic diseases, are tell-tale molecules that could be used to monitor health status, disease onset, treatment response and outcome. Informative biomarkers can further serve as early sentinels of disease, and this has been considered as the most promising alternative to classic environmental epidemiology<sup>71, 130</sup>

The salivary microbiota is a potential diagnostic indicator of several diseases. Culture-independent techniques are required to study the salivary microbial community since many of its members have not been cultivated.

The study of the oral microbiota as well as its salivary component requires culture-independent techniques, since about one third of 700 bacterial species identified in the human oral cavity have not been cultivated . These may be based on PCR amplification and high-throughput sequencing of the bacterial 16S rRNA genes (16S-HTS) or the metagenomic whole genome shotgun (WGS) sequencing<sup>39, 57</sup>. The latter approach may include either the analysis of the totality of generated DNA fragments or of the 16S rRNA gene fragments retrieved from the metagenome (16S-WGS). Both 16S-WGS and 16S-HTS approach presents limitations and advantages over each other<sup>3, 84</sup>.

### **Salivary proteome: human salivary proteome project**

Human salivary proteome analysis is of importance, as it helps us understand oral health in general and the pathogenesis of a disease. Three research groups

were funded by the National Institute of Dental and Craniofacial Research / National Institutes of Health to decipher comprehensively the human salivary proteome. Significant progress has been made in cataloguing human saliva proteins and exploring their post-translational modifications <sup>78</sup>.

By using both two-dimensional gel electrophoresis / mass spectrometry and ‘shotgun’ proteomics approaches, we identified 309 distinct proteins in human whole saliva. In addition, after 3 years of collective identification and cataloguing of the salivary proteome by the three National Institute of Dental and Craniofacial Research-support salivary proteome projects, the first complete profile of the salivary secretory proteome has been completed. Collectively, 1166 salivary proteins have been identified: 914 from the parotid fluid and 917 from the combined submandibular and sublingual fluids <sup>30</sup>. The University of California at Los Angeles is the data-centralization site, harbouring the entire database of the human salivary proteome known as the ‘Salivary Proteome Knowledge Base’ is a genome-wide view of the distribution of the parotid and combined submandibular and sublingual fluid proteomes <sup>44, 62</sup>.

### **Salivary transcriptome**

Based on earlier studies it was found that RNA molecules are elevated in the cases of oral cancer tissues and their levels in saliva are also high, which also prompted to the examination of the scope and complexity of RNA present in human saliva. High-density oligonucleotide microarrays (Affymetrix HG U133A) were used to profile salivary mRNA and revealed that there are ~3,000 human mRNAs in the cell-free saliva supernatant of healthy subjects.

Of particular interest is that there is a normal saliva transcriptome core signature of 185 mRNAs that is present in all normal subjects, providing the rationale to use the salivary transcriptome for disease detection<sup>34, 80</sup>.

The presence of human mRNA in saliva may seem to be surprising. However, it was shown that endogenous mRNA is protected from immediate degradation in a similar manner as cell-free RNA in plasma. The utilization of cell-free RNA has been widely accepted. Two recent studies demonstrated that foetal cell-free RNA crossed the placenta and was detected in maternal serum. The first study involved the non-invasive determination of foetal aneuploidies from maternal plasma<sup>99</sup>. The second study was a gene-expression microarray investigation of maternal and foetal whole blood that identified foetal mRNA markers in maternal blood that are independent of gender or polymorphism<sup>131</sup>.

Other research groups, particularly from forensic sciences, are focusing on multiplex mRNA profiling for the identification of body fluids, including saliva. Most recently a Dutch forensic group was able to perform a gene-expression profile on saliva stains from crime scenes, leading to the identification of five saliva RNA markers (SPRR3, SPRR1A, KRT4, KRT6A and KRT13), stable for up to 180 days, which can be used for the identification of blood and saliva stains in forensic practice. Of importance is that these five saliva RNA markers selected for forensic applications are all in the normal saliva transcriptome core of 185 mRNAs, substantiating and independently validating our data. Lastly, **Shaw** and co-workers have identified a biomarker, amylase, which is highly correlated with sleep drive.

Importantly, both salivary amylase activity and mRNA levels are also responsive to extended waking in humans. These studies provide firm support for our work by showing that mRNA can be extracted from human saliva and used to develop standard tests <sup>46, 111</sup>.

### **Immunologic and enzymatic assays**

Enzyme-linked immunosorbent assay (ELISA) and Immunofluorescence techniques are basically antibody-based methods used to enumerate the specific species of microorganisms without actually cultivating the species. It is dependent on the specificity of developed antibodies to specific taxa. These techniques have the advantage that samples don't necessarily have to be cultured for their enumeration; they are rapid and less expensive than the method which involves a culture. However, they are limited to species for which reagents have been developed. It is difficult to use these techniques to evaluate species in large numbers of plaque samples and it is time-consuming to develop and validate specific antisera to new species <sup>61, 134</sup>.

### **DNA – DNA hybridization or checkerboard**

DNA-DNA hybridization is a molecular approach used to detect bacteria based on the hybridization of the target species to the ones that are the labelled genomic DNA that has been attached to nylon membranes. Based on extensive research and studies conducted by **LoescheWJ et al**, **Haffajee** <sup>83</sup>**Ximenez-Fyvie LA**, **Feres M et al** <sup>118</sup> and **Socransky** <sup>104</sup> have reported that the levels of limited number of species with this method is found in adult periodontitis,

periodontal health, refractory periodontitis and response to therapy. This method provides a major benefit for studies conducted on the oral microbial ecology due to advantages such as detection of multiple species from each sample simultaneously, and enabling the ease of study when it comes to a large sample size for large numbers of species<sup>136</sup>. Checkerboard technique is a rapid, sensitive, and relatively inexpensive technique. It is also dependent on a culture technique to cultivate the target species for creating genomic probes. Like antibody-based assays, cross reactivity can be verified only with cultivated species hence specificity of the probe is an unknown variable.

#### **Polymerase chain reaction**

**Kary Mullis** first developed the technique of polymerase chain reaction (PCR), which was used to amplify specific genes or parts of genes which are then used to identify bacterial species from which they had originally originated from<sup>61</sup>. In a study conducted by **Kumar PS et al (2005)**<sup>24, 66</sup> species-specific PCR primers were designed and used in individual PCR reactions to detect prevalence of target species in plaque samples of healthy and diseased subjects. These studies confirmed that several species, including the ones that were uncultivated, were associated with oral health or periodontitis<sup>21, 89</sup>. Given the appropriate primers, this method is of a rapid, simple nature, can detect small numbers of cells of a given species, and indicates the presence or absence of a species in the sample. It has certain disadvantages of not providing data, and it may not be cost effective for a larger sample size and for applications where relative levels of species are important, PCR may not be ideal.

## **DNA Probes**

Oligonucleotide probes are short probes that are designed to identify unique regions of DNA within cells of a given bacterial species. These probes are highly specific and the likelihood of cross-reactions with other species is extremely low <sup>129</sup>. Because they usually target a limited segment of DNA of an organism, oligonucleotide probes tend to be less sensitive for detection of low numbers of bacteria than whole genomic probes.

Whole genomic DNA probes are constructed utilizing the entire genome of a bacterial species as the target and therefore can be quite sensitive. This in turn may increase the probability of cross-reactions between species because of common regions of DNA among closely related species <sup>45</sup>. The technique can detect only species for which DNA probes have been prepared, creating a drawback as it cannot detect the novel pathogens or environmentally important species that might be detected in culture or by other molecular techniques.

## **OPEN ENDED APPROACHES- 16S rRNA sequencing analysis:**

Open ended approaches usually allow identification of even uncultivated and previously unknown species. According to **Spratt (2004)** these approaches are based on the 16 S rRNA sequencing, it's amplification and resulting analysis of the 16S rRNA genes present within a microbiome sample. 16S rRNA has proven to be the most useful phylogenetic marker to identify bacteria and in turn determine their evolutionary relationships <sup>23, 102</sup>. Ribosomal RNA gene is essential for life and present in all prokaryotes. It contains nucleic acid sequences with variable and highly conserved regions;



these conserved regions are used to design universal PCR primers which are capable of recognizing segments of 16S rRNA gene sequence of all bacterial species and hypervariable regions are used as signatures to discriminate one species from another. 16S rRNA gene is large enough (about 1500 bases) to provide sufficient sequence variability among bacteria, thereby making comparisons possible at different taxonomic levels<sup>39</sup>.

DNA and protein sequencing started in the 1970s when the virus Lambda (50,000 nucleotides) was sequenced by **Sanger et al. Frederick Sanger** and colleagues. They described the use of chain-terminating dideoxynucleotide analogues that caused base-specific termination of primed DNA synthesis and this came to be popularly known as Sanger sequencing method. This method of sequencing was then considered to be of gold standard, and over the years, whole genome sequencing of many bacteria has been carried out using this method. Sanger technology was used in the sequencing of the first human genome, which was completed in 2003 through the ***Human Genome Project***, a 13-year effort with an estimated cost of 2.7 billion dollars<sup>74</sup>

Over the past decade, next generation sequencing technologies have emerged, which are high throughput and they are able to generate three to four orders of magnitude more sequences and are also relatively less expensive.

## **NEXT GENERATION SEQUENCING TECHNOLOGY (NGS):**

Next generation sequencing method employs a wide spectrum of technologies such as: sequencing by ligation, sequencing by synthesis, single molecule DNA sequencing and colony sequencing. NGS is performed by repeated cycles of polymerase-mediated nucleotide extensions or by machinery automated cyclical ligation of oligonucleotides <sup>7</sup>.

### **Fundamentals of NGS platforms:**

NGS platforms share a common technological feature—massive parallel sequencing of clonally amplified or single DNA molecules that are spatially separated in a flow cell<sup>7, 115</sup>. This design is a paradigm shift from that of Sanger sequencing, which is based on electrophoretic separation of chain-termination products produced in individual sequencing reactions. In NGS, sequencing is performed by repeated cycles of polymerase-mediated nucleotide extensions or, in one format, by iterative cycles of oligonucleotide ligation. As a massively parallel process, NGS generates hundreds of megabases to gigabases of nucleotide sequence output in a single instrument run, depending on the platform. The 2 basic procedures are ligation of DNA fragments with oligonucleotide adaptors and fragment immobilization to a solid surface, such as a bead <sup>65, 88</sup>.


The three commonly used platforms for massive parallel DNA sequencing at present are the Roche/454 FLX, the Illumina/ Solexa Genome Analyze <sup>34,75</sup> and the Applied Biosystems / SOLiD (Life Technologies,

Carlsbad, CA). The most recent powerful NGS platforms have significant reductions in the run time and remarkable data output, they include HiSeq and the Ion Torrent Personal Genome Machine (PGM).

Until recently, the main focus in dental research has been focused on studying a small fraction of the oral microbiome which mainly consisted of opportunistic pathogens. After the advent of next-generation sequencing (NGS) technologies, researchers now have the tools that allow for profiling of the microbiomes and metagenomes at never before thought of depths thereby, creating a massive opportunity to understand the oral microbiome as a whole, better <sup>91</sup>. The major advantages of NGS are the high throughput and the fact that there is no need to target specific taxa. The availability of sequencing facilities and the relatively low cost have contributed to an exponential growth of NGS datasets. Using this technology we have conducted this study, to identify the microbiome associated with implant patients thereby establishing a sound knowledge as to the key colonisers which can further help us identify and rectify any future implant related diseases .



FIGURE 1: BACTERIAL COMPLEXES



Bacterial species	Complex
<i>Actinomyces</i> <i>Veillonella</i>	Purple
<i>Streptococcus: gordonii, intermedius, mitis, sanguis</i>	Yellow
<i>Capnocytophaga</i> <i>E. corrodens</i>	Green
<i>Campilobacter rectus</i> <i>Fusobacterium nucleatum</i> <i>P. micros</i> <i>P. intermedia</i>	Orange
<i>T. forsythia</i> <i>P. gingivalis</i> <i>T. denticola</i>	Red
<i>A. actinomycetemcomitans</i> <i>Selenomonas</i>	Not grouped

**FIGURE 2: ROCHE 454 LIFE SCIENCES SYSTEM**





FIGURE 3: ILLUMINA SOLEXA GENOME ANALYZER



# *Materials and Methods*

---

---



## **MATERIALS AND METHODS**

### **Study population**

Individuals seeking dental treatment in Ragas Dental College and Hospital, Chennai were used in the present study. Certificate of Ethical clearance for the study was obtained from the Institutional Review Board of Ragas Dental College. Twenty patients fitting the aim of the study visiting the dental out-patient facility

Saliva samples were obtained from the patients after obtaining their consent. Twenty patients fitting the aim of the study visiting the dental out-patient facility were included in the study. They were split into two groups of ten each. The first group consisted of periodontally healthy individuals and was designated as **Group H** (Control Group). The second group consisted of individuals who had endosseous implants placed in their oral cavity 6 months post loading of the prosthesis and they were designated as **Group I** (Test Group).

The **American Academy of Periodontology** (AAP) has defined periodontal health as “The condition of a patient when there is function without evidence of disease or abnormality”<sup>4</sup>.

The diagnostic definition of peri-implant health is based on the following criteria: 1) absence of peri-implant signs of soft tissue inflammation (redness, swelling, profuse bleeding on probing), and 2) the absence of further additional bone loss following initial healing<sup>72</sup>.

In general, however, the probing depth associated with peri-implant health should be  $\leq 5.0$  mm<sup>109</sup>.

**Control group** comprised of ten subjects with clinically non-inflamed, healthy gingiva having probing pocket depth of (PPD) lesser than or equal to 3mm, with no signs of clinical attachment loss (CAL) and no bleeding on Probing (BOP).

**Test group** comprised of ten subjects with endosseous implants placed in their oral cavity 6 months post loading of prosthesis, and the clinical signs taken into consideration were healthy peri-implant gingiva having probing pocket depth of (PPD) lesser than or equal to 4mm, with no signs of clinical attachment loss (CAL) and no bleeding on Probing (BOP).

#### **INCLUSION CRITERIA**

- Subjects included in this study were expected to exhibit good general health
- Subjects should have met the criteria of periodontal health as described above

#### **EXCLUSION CRITERIA**

- Patient with systemic disorders, such as diabetes mellitus or immunological disorders, HIV.
- Patients on drugs that have potential to interfere with the study such as immunosuppressant drugs or steroids.

- Patients with history of tobacco usage.
- Patients under antimicrobial therapy for the past 6 months

**SALIVA SAMPLE COLLECTION:-**

- Unstimulated whole saliva was collected in sterile salivary sample tubs in the morning and subjects refrained from eating, drinking, smoking or performing any oral hygiene for at least 2 hours prior to the collection following **Navazesh** method of saliva collection.
- Participants were instructed not to consume food or beverages an hour before the sample collection.
- The patients were asked to rinse their mouth and wait at least 10 minutes before providing a specimen
- Clear and comprehensible labeling of containers was done. (**‘H’** for healthy samples and **‘I’** for implant samples, each healthy and implant sample designated with a number for keeping count of the patient samples that were collected)
- Samples were frozen and stored at -80°C until the sample collection period is completed.
- Salivary Samples were sent for **Next Generation Sequencing** for microbiome analysis to a laboratory after being packaged in containers with geo packs to maintain the temperature

### **PCR KIT CONTENTS**

- 10mM Tris pH 8.5
- AMPure XP beads
- Freshly Prepared 80% Ethanol (EtOH)
- 96-well 0.2 ml PCR plate
- Microseal 'B' seal
- 96-well MIDI plate

### **PROCEDURE**

#### **DNA extraction, 16S rRNA amplification, library construction and sequencing**

Genomic DNA was extracted from the ten saliva samples obtained from patients with dental implants placed in their oral cavity 6 months post loading with the Fast DNA kit and the FastPrep24-5G instrument according to manufacturer's recommendations (MP Biomedicals, Santa Ana, CA). Extracted DNA was then purified with silica-based spin filters (FastDNA kit) and the DNA was amplified using the 16S V3 (341F) forward and V4 (805R) reverse primer pairs with added Illumina adapter overhang nucleotide sequences.

The amplicon generation was done using PCR to amplify a template out of a DNA sample using the region-of-interest specific primers with overhang adapters attached. Amplicon synthesis was then performed using thermocycling with 2.5µl of microbial DNA (5ng/ µl), 5µl of amplicon PCR

forward primer (1 $\mu$ M), 5 $\mu$ l of amplicon PCR reverse primer (1 $\mu$ M), and 12.5 $\mu$ l of 2x KAPA HiFi HotStart Ready Mix (Kapa Biosystems) at 95°C. Initial denaturation for 3 minutes, followed by 25 cycles of 95°C for 30 seconds, 55°C for 30 seconds, and 72°C for 30 seconds, and a final extension at 72°C for 5 minutes.

Reactions were cleaned up with Agencourt AMPure XP beads (Beckman Coulter Genomics) according to the protocol specified by the manufacturer. Attachment of dual indices and Illumina sequencing adapters was performed using 5 $\mu$ l of amplicon PCR product DNA, 5 $\mu$ l of Illumina Nextera XT Index 1 Primer (N7xx) from the Nextera XT Index kit, 5  $\mu$ l of Nextera XT Index 2 Primer (S5xx), 25  $\mu$ l of 2x KAPA HiFi HotStart Ready Mix, and 10 $\mu$ l of PCR-grade water (UltraClean DNA-free PCR water; MO BIO Laboratories, Inc., Carlsbad, CA, USA), with thermocycling at 95°C for 3 minutes, followed by 8 cycles of 95°C for 30 seconds, 55°C for 30 seconds, and 72 °C for 30 seconds, and a final extension at 72 °C for 5 minutes.

Constructed 16S metagenomic libraries were then purified with Agencourt AMPure XP beads and quantified using a fluorometric quantification method that uses dsDNA binding dyes with Quant-iT PicoGreen and the KAPA Library Quantification Kit (KAPABIOSYSTEMS). Library quality control was performed using the Agilent Technologies 2100 Bioanalyzer to ascertain the quality and average size distribution.

Samples were denatured and diluted to a final concentration of 10 pM with a 20 % PhiX (Illumina) control. Sequencing was performed using the

Illumina Miseq System. After samples are loaded, the MiSeq system provides on instrument secondary analysis using the MiSeq Reporter software (MSR). All eight samples were multiplexed and sequenced in a single lane on the MiSeq using  $2 \times 300$  bp paired-end sequencing. Operational taxonomic units (OTUs) were assigned to each sequence using Human Oral Microbiome Database. The Metagenomics workflow classified organisms from the V3 and V4 amplicon using a database of 16S rRNA data, and this classification is based on the Greengenes database. The output of this workflow is a classification of reads at various taxonomic levels: kingdom, phylum, class, order, family, genus, and species. The analysis output is represented using Bar Graphs, Tables and Cluster Pie Charts.

### **Statistical analysis**

Data was analyzed as recommended by studies conducted previously. Data obtained was compiled systematically using the excel spreadsheet provided by Microsoft Office, the dataset was then subdivided and distributed meaningfully and presented as graphs and tables.

Statistical analysis was performed using the Statistical Package of Social Sciences software (IBM Corp. Released 2011. SPSS Statistics for Windows, version 20.0 Armonk, NY: IBM Corp). Normality test was done using Kolmogorov-Smirnov test and Shapiro-Wilk numerical test, and it was observed that all the variables were normally distributed. Depending on the nature of the data, appropriate parametric statistical tests were chosen. P value of  $<0.05$  was considered to be significant.

# *Photographs*

---



**IMAGE 1: HEALTHY PERIODONTIUM**



**IMAGE 2: IMPLANT PLACEMENT AND POST LOADING**



**IMAGE 3: STERILE SALIVARY TUB**




**IMAGE 4: ILLUMINA SEQUENCING**


NextSeq Series




IMAGE 5: 4 BASIC STEPS IN ILLUMINA NGS WORK FLOW



**IMAGE 6: PARTIAL END SEQUENCING AND ALIGNMENT**



**Typical workflow for metagenomic data analysis**



## *Results*

---

---

## RESULTS

The present study was carried out among a population of twenty individuals seeking dental treatment in Ragas Dental College and Hospital, Chennai. The age of the patients were categorized to be greater than 30 years with a mean age of 35.4 years.

Unstimulated saliva samples were collected using sterile containers from ten periodontally healthy control individuals (designated as H1, H2, H3 ...H10) and from implant patients six months post loading (designated as I1, I2, I3...I10).

Amplicons from V3-V4 hypervariable regions of 16S rRNA gene underwent sequencing. The results obtained from the sequencing process are represented according to taxonomic classification system of bacteria, and the individual comparisons are depicted via tables and graphs.

### **Distribution of bacteria in healthy and implant sites:**

The distribution of bacteria in the healthy and implant sites based on phylum level, genus and species are depicted in Table 1 and Graph 1-A, 1-B and 1-C. In the healthy sites, a total of 10 phyla, 53 genera and 187 species; and in implant sites 11 phyla, 60 genera and 228 species have been identified.

### Top 5 phyla in healthy and implant sites:

The top 5 phyla in healthy and implant sites along with their respective abundances are depicted in Table 2 and Graph 2-A and 2-B. In healthy sites, phylum Firmicutes has shown highest abundance of 28.63% followed by *Bacteroidetes* (28.43%), *Fusobacteria* (15.9%), *Proteobacteria* (13.32%) and *Actinobacter* (6.56%). In implant sites, phylum *Firmicutes* (31.7%) has shown the highest abundance of 31.7% followed by *Bacteroidetes* (26.1%), *Fusobacteria* (15.49%), *Proteobacteria* (9.23 %) and TM7 (7.33%). **The phylum not present in healthy samples that was present in implant patients was found to be *Synergistetes*.**

### Top 5 genera in healthy and implant sites:

The top 5 genera in healthy and implant sites along with their respective abundances have been depicted in Table 3 and Graph 3-A and 3-B. In both healthy and implant sites, *Prevotella* is the most abundant genus to be identified with an abundance of 12.82% and 12.4% respectively. Following this is *Leptotrichia* with values of 9.14% and 9.23% respectively, the next four genera in healthy sites are *Fusobacterium* (6.75%), *Veillonella* (6.26%), *Porphyromonas* (5.16%) and *Nisseria* (4.97%) and in implant sites are *Saccharibacteria* (6.61%), *Fusobacterium* (6.15%), *Porphyromonas* (5.52%) and *Veillonella* (5.52%). **The genera found in healthy patients that were not present in implant patients are: *Adlercreutzia*, *Anaerococcus*,**

*Bergeyella*, *Clostridiales*, *Johnsonella*, *Odoribacter*, *Johnsonella*, *Pyramidobacter*, *Scardovia*, *Sporanaerobacter*. **The genera found in patient with implants that were not present in healthy patients are:** *Absconditabacteria*, *Anaerovorax*, *Eggerthella*, *Erwinia*, *Novosphingobium*, *Slackia*

**Species present in healthy samples that are not present in implant samples:**

- *Acinetobacter johnsonii*
- *Actinomyces* sp. HMT 175
- *Aggregatibacter paraphrophilus*
- *Aggregatibacter* sp. HMT 513
- *Bifidobacterium animalis*
- *Capnocytophaga* sp. HMT 878
- *Eggerthella lenta*
- *Enterobacter cancerogenus*
- *Enterococcus casseliflavus*
- *Enterococcus saccharolyticus*
- *Filifactor alocis*
- *Gemella bergeri*
- *Haemophilus influenzae*
- *Kingella* sp. HMT 932
- *Klebsiella aerogenes*
- *Lactobacillus crispatus*
- *Novosphingobium panipatense*
- *Peptostreptococcaceae* [XI][G-5] bacterium HMT 493
- *Prevotella* sp. HMT 304
- *Slackia exigua*



**Species present in implant samples that are not present in healthy samples:**

- *Actinomyces oris*
- *Actinomyces sp. HMT 169*
- *Anaerococcus octavius*
- *Bacteroides heparinolyticus*
- *Bacteroidetes [G-3] bacterium HMT 280*
- *Bacteroidetes [G-3] bacterium HMT 436*
- *Bacteroidetes [G-5] bacterium HMT 505*
- *Bacteroidetes [G-6] bacterium HMT 516*
- *Bulleidia extructa*
- *Butyrivibrio sp. HMT 080*
- *Capnocytophaga sp. HMT 324*
- *Capnocytophaga sp. HMT 338*
- *Clostridiales [F-1][G-1] bacterium HMT 093*
- *Dialister pneumosintes*
- *Enterococcus faecalis*
- *Fretibacterium fastidiosum*
- *Fretibacterium sp. HMT 360*
- *Gracilibacteria (GN02) [G-1] bacterium HMT 871*
- *Johnsonella sp. HMT 166*
- *Lactobacillus fermentum*
- *Lactobacillus gasseri*
- *Lactobacillus salivarius*
- *Leptotrichia sp. HMT 879*
- *Neisseria sp. HMT 018*
- *Oribacterium sp. HMT 102*
- *Peptoniphilaceae [G-2] bacterium HMT 790*
- *Peptostreptococcaceae [XI][G-1] infirmum*
- *Peptostreptococcaceae [XI][G-4] bacterium HMT 369*
- *Peptostreptococcaceae [XI][G-5] saphenum*
- *Peptostreptococcaceae [XI][G-6] minutum*
- *Peptostreptococcaceae [XI][G-6] nodatum*
- *Peptostreptococcaceae [XI][G-7] bacterium HMT 081*
- *Prevotella dentalis*
- *Prevotella enoeca*
- *Prevotella multiformis*
- *Prevotella multisaccharivorax*
- *Prevotella sp. HMT 526*

- *Pseudopropionibacterium propionicum*
- *Pyramidobacter piscolens*
- *Saccharibacteria (TM7) [G-1] bacterium HMT 488*
- *Scardovia wiggsiae*
- *Selenomonas artemidis*
- *Selenomonas diana*
- *Selenomonas sp. HMT 126*
- *Selenomonas sp. HMT 133*
- *Selenomonas sp. HMT 137*
- *Selenomonas sp. HMT 146*
- *Selenomonas sp. HMT 149*
- *Selenomonas sp. HMT 388*
- *Selenomonas sp. HMT 442*
- *Selenomonas sp. HMT 479*
- *Stomatobaculum sp. HMT 097*
- *Streptococcus sobrinus*
- *Treponema amylovorum*
- *Treponema parvum*
- *Treponema sp. HMT 230*
- *Treponema sp. HMT 231*
- *Treponema sp. HMT 238*
- *Treponema sp. HMT 249*
- *Treponema sp. HMT 258*
- *Treponema sp. HMT 517*
- *Treponema vincentii*
- *Veillonella sp. HMT 917*
- *Veillonellaceae [G-1] bacterium HMT 135*
- *Veillonellaceae [G-1] bacterium HMT 145*
- *Veillonellaceae [G-1] bacterium HMT 483*

### **Comparison of subgingival microbiome in healthy versus gingival recession sites at genus level: phylogenetic tree**

The subgingival microbiome was compared between healthy and gingival recession sites at genus level and is represented in the form of a circular phylogenetic tree in Graph 3-C. The tree has been constructed with phyloT software and is displayed using iTOL (Letunic and Bork, 2011). The

bars on the outer band (maroon), represents the abundance of bacterial genera in healthy (green) and implant sites (blue) sites.

**TABLE 1: DISTRIBUTION OF BACTERIA IN HEALTHY AND IMPLANT**

CRITERIA	PHYLUM	GENUS	SPECIES
HEALTH	10	53	187
IMPLANT	11	60	228

**TABLE 2: TOP 5 PHYLA IN HEALTH AND IMPLANT**

S.No	HEALTH	ABUNDANCE (%)	IMPLANT	ABUNDANCE (%)
1	Firmicutes	28.62823	Firmicutes	31.7029
2	Bacteroidetes	28.42942	Bacteroidetes	26.08696
3	Fusobacteria	15.90457	Fusobacteria	15.48913
4	Proteobacteria	13.32008	Proteobacteria	9.23913
5	Actinobacteria	6.560636	TM7	7.336957

**TABLE 3: TOP 20 GENERA IN HEALTH AND IMPLANT**

S.No	HEALTH	ABUNDANCE (%)	IMPLANT	ABUNDANCE (%)
1	Prevotella	12.82306	Prevotella	12.40942
2	Leptotrichia	9.145129	Leptotrichia	9.32971

3	Fusobacterium	6.759443	Saccharibacteria	6.612319
4	Veillonella	6.262425	Fusobacterium	6.15942
5	Porphyromonas	5.168986	Porphyromonas	5.525362
6	Neisseria	4.970179	Veillonella	5.525362
7	Streptococcus	4.970179	Streptococcus	5.344203
8	Saccharibacteria	4.771372	Capnocytophaga	4.891304
9	Capnocytophaga	4.572565	Selenomonas	2.717391
10	[Prevotella]	3.777336	Oribacterium	2.626812
11	Gemella	2.982107	Gemella	2.536232
12	Oribacterium	2.584493	Neisseria	2.445652
13	Rothia	2.485089	Treponema	1.992754
14	Haemophilus	2.286282	Haemophilus	1.902174
15	Bifidobacterium	2.186879	Campylobacter	1.811594
16	Campylobacter	2.087475	Rothia	1.630435
17	Granulicatella	1.789264	Absconditabacteria	1.630435
18	Absconditabacteria	1.39165	Bifidobacterium	1.539855
19	Actinobacillus	1.39165	Ruminococcus	1.539855
20	Ruminococcaceae	1.39165	Granulicatella	1.358696

**TABLE 4: TOP 20 SPECIES IN HEALTH AND IMPLANT**

S.No	IMPLANT	ABUNDANCE (%)	HEALTH	ABUNDANCE (%)
1	Uncultured	3.26087	Porphyromonas pasteri	2.683897
2	Porphyromonas pasteri	2.807971	Uncultured	2.683897
3	Fusobacterium nucleatum subsp. vincentii	1.992754	Fusobacterium nucleatum subsp. vincentii	2.186879
4	Capnocytophaga sputigena	1.358696	Veillonella parvula	1.590457
5	Veillonella parvula	1.358696	Capnocytophaga sputigena	1.491054
6	Capnocytophaga leadbetteri	1.177536	Alloprevotella sp. HMT 473	1.192843
7	Capnocytophaga granulosa	1.086957	Prevotella veroralis	1.192843
8	Megasphaera micronuciformis	0.996377	Fusobacterium periodonticum	1.093439
9	Catonella morbi	0.905797	Bergeyella sp. HMT 322	0.994036
10	Fusobacterium periodonticum	0.905797	Campylobacter concisus	0.994036
11	Gemella morbillorum	0.905797	Fusobacterium sp. HMT 370	0.994036
12	Granulicatella adiacens	0.905797	Gemella haemolysans	0.994036

13	Haemophilus parainfluenzae	0.905797	Gemella morbilorum	0.994036
14	Leptotrichia hofstadii	0.905797	Gemella sanguinis	0.994036
15	Oribacterium parvum	0.905797	Granulicatella adiacens	0.994036
16	Prevotella sp. HMT 313	0.905797	Haemophilus parainfluenzae	0.994036
17	Prevotella veroralis	0.905797	Neisseria flava	0.994036
18	Saccharibacteria (TM7) [G-1] bacterium HMT 352	0.905797	Oribacterium parvum	0.994036
19	Saccharibacteria (TM7) [G-3] bacterium HMT 351	0.905797	Oribacterium sinus	0.994036
20	Saccharibacteria (TM7) [G-6] bacterium HMT 870	0.905797	Prevotella melaninogenica	0.994036

**TABLE 5: PERIODONTAL HEALTH-ASSOCIATED MICROBIOME**  
**(187 species- present in health, not in implant)**

	A	93	Neisseria flava
1	Abiotrophia defectiva	94	Neisseria flavescens
2	Absconditabacteria (SR1) [G-1] bacterium HMT 345	95	Neisseria oralis
3	Absconditabacteria (SR1) [G-1] bacterium HMT 874	96	Neisseria perflava
4	Absconditabacteria (SR1) [G-1] bacterium HMT 875	97	Neisseria polysaccharea
5	Actinomyces graevenitzii	98	Neisseria subflava
6	Actinomyces sp. HMT 172		O
7	Actinomyces sp. HMT 180	99	Oribacterium asaccharolyticum
8	Aggregatibacter aphrophilus	100	Oribacterium parvum
9	Aggregatibacter paraphrophilus	101	Oribacterium sinus
10	Aggregatibacter segnis		P
11	Aggregatibacter sp. HMT 458	102	Parvimonas micra
12	Alloprevotella rava	103	Parvimonas sp. HMT 393
13	Alloprevotella sp. HMT 308	104	Peptostreptococcaceae [XI][G-1] sulci
14	Alloprevotella sp. HMT 473	105	Peptostreptococcaceae [XI][G-5] bacterium HMT 493
15	Alloprevotella sp. HMT 914	106	Peptostreptococcaceae [XI][G-7] bacterium HMT 922
16	Alloprevotella tanneriae	107	Peptostreptococcaceae [XI][G-7] yurii subsp. yurii & margaretae
17	Atopobium parvulum	108	Peptostreptococcaceae [XI][G-9] brachy
18	Atopobium rimae	109	Peptostreptococcus stomatis
	B	110	Porphyromonas catoniae
19	Bacteroidales [G-2] bacterium HMT 274	111	Porphyromonas endodontalis
20	Bergeyella sp. HMT 206	112	Porphyromonas gingivalis
21	Bergeyella sp. HMT 322	113	Porphyromonas pasteri



22	<i>Bifidobacterium breve</i>	114	<i>Porphyromonas</i> sp. HMT 275
23	<i>Bifidobacterium dentium</i>	115	<i>Porphyromonas</i> sp. HMT 277
24	<i>Bifidobacterium longum</i>	116	<i>Porphyromonas</i> sp. HMT 278
25	<i>Bifidobacterium scardovii</i>	117	<i>Porphyromonas</i> sp. HMT 284
	C	118	<i>Porphyromonas</i> sp. HMT 285
26	<i>Campylobacter concisus</i>	119	<i>Porphyromonas</i> sp. HMT 930
27	<i>Campylobacter gracilis</i>	120	<i>Prevotella aurantiaca</i>
28	<i>Campylobacter rectus</i>	121	<i>Prevotella denticola</i>
29	<i>Campylobacter</i> sp. HMT 044	122	<i>Prevotella histicola</i>
30	<i>Capnocytophaga granulosa</i>	123	<i>Prevotella loescheii</i>
31	<i>Capnocytophaga leadbetteri</i>	124	<i>Prevotella maculosa</i>
32	<i>Capnocytophaga</i> sp. HMT 326	125	<i>Prevotella melaninogenica</i>
33	<i>Capnocytophaga</i> sp. HMT 332	126	<i>Prevotella micans</i>
34	<i>Capnocytophaga</i> sp. HMT 335	127	<i>Prevotella nanceiensis</i>
35	<i>Capnocytophaga</i> sp. HMT 336	128	<i>Prevotella nigrescens</i>
36	<i>Capnocytophaga sputigena</i>	129	<i>Prevotella oralis</i>
37	<i>Cardiobacterium hominis</i>	130	<i>Prevotella oris</i>
38	<i>Catonella morbi</i>	131	<i>Prevotella oulorum</i>
39	<i>Corynebacterium durum</i>	132	<i>Prevotella pallens</i>
	D	133	<i>Prevotella pleuritidis</i>
40	<i>Dialister invisus</i>	134	<i>Prevotella salivae</i>
	E	135	<i>Prevotella scopos</i>
41	<i>Eggerthella lenta</i>	136	<i>Prevotella shahii</i>
42	<i>Enterococcus durans</i>	137	<i>Prevotella</i> sp. HMT 305
43	<i>Enterococcus italicus</i>	138	<i>Prevotella</i> sp. HMT 306
44	<i>Escherichia coli</i>	139	<i>Prevotella</i> sp. HMT 309
	F	140	<i>Prevotella</i> sp. HMT 313

45	<i>Finegoldia magna</i>	141	<i>Prevotella</i> sp. HMT 314
46	<i>Fusobacterium naviforme</i>	142	<i>Prevotella</i> sp. HMT 317
47	<i>Fusobacterium nucleatum</i> subsp. <i>animalis</i>	143	<i>Prevotella</i> sp. HMT 443
48	<i>Fusobacterium nucleatum</i> subsp. <i>polymorphum</i>	144	<i>Prevotella</i> sp. HMT 472
49	<i>Fusobacterium nucleatum</i> subsp. <i>vincentii</i>	145	<i>Prevotella</i> sp. HMT 475
50	<i>Fusobacterium periodonticum</i>	146	<i>Prevotella veroralis</i>
51	<i>Fusobacterium</i> sp. HMT 203		R
52	<i>Fusobacterium</i> sp. HMT 370	147	<i>Rothia aerea</i>
	G	148	<i>Rothia dentocariosa</i>
53	<i>Gemella haemolysans</i>	149	<i>Rothia mucilaginosa</i>
54	<i>Gemella morbillorum</i>	150	Ruminococcaceae [G-1] bacterium HMT 075
55	<i>Gemella sanguinis</i>	151	Ruminococcaceae [G-2] bacterium HMT 085
56	<i>Gracilibacteria</i> (GN02) [G-2] bacterium HMT 873		S
57	<i>Granulicatella adiacens</i>	152	<i>Saccharibacteria</i> (TM7) [G-1] bacterium HMT 346
58	<i>Granulicatella elegans</i>	153	<i>Saccharibacteria</i> (TM7) [G-1] bacterium HMT 347
	H	154	<i>Saccharibacteria</i> (TM7) [G-1] bacterium HMT 348
59	<i>Haemophilus haemolyticus</i>	155	<i>Saccharibacteria</i> (TM7) [G-1] bacterium HMT 349
60	<i>Haemophilus parainfluenzae</i>	156	<i>Saccharibacteria</i> (TM7) [G-1] bacterium HMT 352
61	<i>Haemophilus paraphrohaemolyticus</i>	157	<i>Saccharibacteria</i> (TM7) [G-1] bacterium HMT 869
62	<i>Haemophilus pittmaniae</i>	158	<i>Saccharibacteria</i> (TM7) [G-2] bacterium HMT 350
63	<i>Haemophilus</i> sp. HMT 036	159	<i>Saccharibacteria</i> (TM7) [G-3] bacterium HMT 351
64	<i>Haemophilus</i> sp. HMT 908	160	<i>Saccharibacteria</i> (TM7) [G-5] bacterium HMT 356
65	<i>Haemophilus sputorum</i>	161	<i>Saccharibacteria</i> (TM7) [G-6] bacterium HMT 870
	K	162	<i>Selenomonas noxia</i>

66	Kingella oralis	163	Selenomonas sp. HMT 136
67	Klebsiella pneumoniae	164	Shuttleworthia satellites
	L	165	Solobacterium moorei
68	Lachnoanaerobaculum orale	166	Stomatobaculum longum
69	Lachnoanaerobaculum umeaense	167	Stomatobaculum sp. HMT 097
70	Lautropia mirabilis	168	Streptococcus lactarius
71	Leptotrichia buccalis	169	Streptococcus mitis
72	Leptotrichia goodfellowii	170	Streptococcus oralis subsp. dentisani clade 058
73	Leptotrichia hofstadii	171	Streptococcus parasanguinis clade 411
74	Leptotrichia hongkongensis	172	Streptococcus peroris
75	Leptotrichia shahii	173	Streptococcus pneumoniae
76	Leptotrichia sp. HMT 212	174	Streptococcus salivarius
77	Leptotrichia sp. HMT 215	175	Streptococcus sanguinis
78	Leptotrichia sp. HMT 217	176	Streptococcus thermophilus
79	Leptotrichia sp. HMT 218		T
80	Leptotrichia sp. HMT 221	177	Tannerella forsythia
81	Leptotrichia sp. HMT 225	178	Tannerella sp. HMT 286
82	Leptotrichia sp. HMT 392	179	Tannerella sp. HMT 808
83	Leptotrichia sp. HMT 417	180	Treponema socranskii
84	Leptotrichia sp. HMT 463		U
85	Leptotrichia sp. HMT 498	181	Uncultured
86	Leptotrichia sp. HMT 847		V
87	Leptotrichia wadei	182	Veillonella atypica
	M	183	Veillonella denticariosi
88	Megasphaera micronuciformis	184	Veillonella dispar
89	Mycoplasma orale	185	Veillonella parvula
90	Mycoplasma salivarium	186	Veillonella rogosae

	N	187	Veillonella sp. HMT 780
91	Neisseria cinerea		
92	Neisseria elongata		

**TABLE 6: IMPLANT ASSOCIATED MICROBIOME (228 species)**


	A	115	Oribacterium parvum
1	Abiotrophia defectiva	116	Oribacterium sinus
2	Absconditabacteria (SR1) [G-1] bacterium HMT 345	117	Oribacterium sp. HMT 078
3	Absconditabacteria (SR1) [G-1] bacterium HMT 874		P
4	Absconditabacteria (SR1) [G-1] bacterium HMT 875	118	Parvimonas micra
5	Actinomyces graevenitzi	119	Parvimonas sp. HMT 393
6	Actinomyces sp. HMT 180	120	Peptostreptococcaceae [XI][G-1] sulci
7	Aggregatibacter segnis	121	Peptostreptococcaceae [XI][G-7] bacterium HMT 081
8	Aggregatibacter sp. HMT 458	122	Peptostreptococcaceae [XI][G-9] brachy
9	Aggregatibacter sp. HMT 949	123	Peptostreptococcus stomatis
10	Alloprevotella rava	124	Porphyromonas catoniae
11	Alloprevotella sp. HMT 308	125	Porphyromonas endodontalis
12	Alloprevotella sp. HMT 473	126	Porphyromonas gingivalis
13	Alloprevotella tannerae	127	Porphyromonas pasteri
14	Anaeroglobus geminatus	128	Porphyromonas sp. HMT 275
15	Atopobium parvulum	129	Porphyromonas sp. HMT 277
16	Atopobium rimae	130	Porphyromonas sp. HMT 278
	B	131	Porphyromonas sp. HMT 284
17	Bacteroidaceae [G-1] bacterium HMT 272	132	Porphyromonas sp. HMT 285
18	Bacteroidales [G-2] bacterium HMT 274	133	Porphyromonas sp. HMT 930
19	Bacteroides heparinolyticus	134	Prevotella aurantiaca
20	Bacteroidetes [G-3] bacterium HMT 280	135	Prevotella baroniae
21	Bacteroidetes [G-3] bacterium HMT 436	136	Prevotella buccae
22	Bacteroidetes [G-5] bacterium HMT 511	137	Prevotella denticola
23	Bacteroidetes [G-6] bacterium HMT 516	138	Prevotella histicola
24	Bergeyella sp. HMT 206	139	Prevotella intermedia
25	Bergeyella sp. HMT 322	140	Prevotella loeschei
26	Bifidobacterium breve	141	Prevotella melaninogenica

27	<i>Bifidobacterium dentium</i>	142	<i>Prevotella nanceiensis</i>
28	<i>Bifidobacterium longum</i>	143	<i>Prevotella nigrescens</i>
29	<i>Bifidobacterium scardovii</i>	144	<i>Prevotella oris</i>
30	<i>Butyrivibrio</i> sp. HMT 080	145	<i>Prevotella oulorum</i>
31	<i>Butyrivibrio</i> sp. HMT 455	146	<i>Prevotella pallens</i>
	C	147	<i>Prevotella pleuritidis</i>
32	<i>Campylobacter concisus</i>	148	<i>Prevotella saccharolytica</i>
33	<i>Campylobacter gracilis</i>	149	<i>Prevotella salivae</i>
34	<i>Campylobacter rectus</i>	150	<i>Prevotella scopos</i>
35	<i>Campylobacter</i> sp. HMT 044	151	<i>Prevotella shahii</i>
36	<i>Capnocytophaga granulosa</i>	152	<i>Prevotella</i> sp. HMT 300
37	<i>Capnocytophaga leadbetteri</i>	153	<i>Prevotella</i> sp. HMT 301
38	<i>Capnocytophaga</i> sp. HMT 323	154	<i>Prevotella</i> sp. HMT 306
39	<i>Capnocytophaga</i> sp. HMT 326	155	<i>Prevotella</i> sp. HMT 309
40	<i>Capnocytophaga</i> sp. HMT 332	156	<i>Prevotella</i> sp. HMT 313
41	<i>Capnocytophaga</i> sp. HMT 336	157	<i>Prevotella</i> sp. HMT 314
42	<i>Capnocytophaga</i> sp. HMT 412	158	<i>Prevotella</i> sp. HMT 317
43	<i>Capnocytophaga</i> sp. HMT 863	159	<i>Prevotella</i> sp. HMT 443
44	<i>Capnocytophaga</i> sp. HMT 864	160	<i>Prevotella</i> sp. HMT 472
45	<i>Capnocytophaga sputigena</i>	161	<i>Prevotella</i> sp. HMT 526
46	<i>Cardiobacterium hominis</i>	162	<i>Prevotella veroralis</i>
47	<i>Catonella morbi</i>		R
48	<i>Centipeda periodontii</i>	163	<i>Rothia aeria</i>
49	<i>Corynebacterium durum</i>	164	<i>Rothia dentocariosa</i>
	D	165	<i>Rothia mucilaginosa</i>
50	<i>Dialister invisus</i>	166	<i>Ruminococcus</i> [G-1] bacterium HMT 075
	E	167	<i>Ruminococcus</i> [G-2] bacterium HMT 085
51	<i>Eikenella corrodens</i>		S
	F	168	<i>Saccharibacteria</i> (TM7) [G-1] bacterium HMT 346
52	<i>Filifactor alocis</i>	169	<i>Saccharibacteria</i> (TM7) [G-1] bacterium HMT 347
53	<i>Finegoldia magna</i>	170	<i>Saccharibacteria</i> (TM7) [G-1] bacterium HMT 348
54	<i>Fretibacterium</i> sp. HMT 362	171	<i>Saccharibacteria</i> (TM7) [G-1] bacterium HMT 349
55	<i>Fusobacterium naviforme</i>	172	<i>Saccharibacteria</i> (TM7) [G-1] bacterium HMT 352
56	<i>Fusobacterium nucleatum</i> subsp. <i>animalis</i>	173	<i>Saccharibacteria</i> (TM7) [G-1] bacterium HMT 488

57	<i>Fusobacterium nucleatum</i> subsp. <i>nucleatum</i>	174	<i>Saccharibacteria</i> (TM7) [G-2] bacterium HMT 350
58	<i>Fusobacterium nucleatum</i> subsp. <i>polymorphum</i>	175	<i>Saccharibacteria</i> (TM7) [G-3] bacterium HMT 351
59	<i>Fusobacterium nucleatum</i> subsp. <i>vincentii</i>	176	<i>Saccharibacteria</i> (TM7) [G-5] bacterium HMT 356
60	<i>Fusobacterium periodonticum</i>	177	<i>Saccharibacteria</i> (TM7) [G-6] bacterium HMT 870
61	<i>Fusobacterium</i> sp. HMT 203	178	<i>Saccharibacteria</i> (TM7) [G-8] bacterium HMT 955
62	<i>Fusobacterium</i> sp. HMT 370	179	<i>Selenomonas diana</i>
	G	180	<i>Selenomonas noxia</i>
63	<i>Gemella haemolysans</i>	181	<i>Selenomonas</i> sp. HMT 134
64	<i>Gemella morbillorum</i>	182	<i>Selenomonas</i> sp. HMT 136
65	<i>Gemella sanguinis</i>	183	<i>Selenomonas</i> sp. HMT 137
66	<i>Gracilibacteria</i> (GN02) [G-1] bacterium HMT 871	184	<i>Selenomonas</i> sp. HMT 146
67	<i>Gracilibacteria</i> (GN02) [G-1] bacterium HMT 872	185	<i>Selenomonas</i> sp. HMT 478
68	<i>Gracilibacteria</i> (GN02) [G-2] bacterium HMT 873	186	<i>Selenomonas</i> sp. HMT 479
69	<i>Granulicatella adiacens</i>	187	<i>Selenomonas sputigena</i>
70	<i>Granulicatella elegans</i>	188	<i>Shuttleworthia satellites</i>
	H	189	<i>Solobacterium moorei</i>
71	<i>Haemophilus haemolyticus</i>	190	<i>Stomatobaculum longum</i>
72	<i>Haemophilus parainfluenzae</i>	191	<i>Stomatobaculum</i> sp. HMT 097
73	<i>Haemophilus paraphrohaemolyticus</i>	192	<i>Streptococcus anginosus</i>
74	<i>Haemophilus pittmaniae</i>	193	<i>Streptococcus cristatus</i> clade 578
75	<i>Haemophilus</i> sp. HMT 036	194	<i>Streptococcus gordonii</i>
76	<i>Haemophilus</i> sp. HMT 908	195	<i>Streptococcus lactarius</i>
77	<i>Haemophilus sputorum</i>	196	<i>Streptococcus mitis</i>
	J	197	<i>Streptococcus parasanguinis</i> clade 411
78	<i>Johnsonella</i> sp. HMT 166	198	<i>Streptococcus peroris</i>
	K	199	<i>Streptococcus pneumoniae</i>
79	<i>Kingella denitrificans</i>	200	<i>Streptococcus salivarius</i>
80	<i>Kingella oralis</i>	201	<i>Streptococcus sanguinis</i>
81	<i>Kingella</i> sp. HMT 012	202	<i>Streptococcus sinensis</i>
	L	203	<i>Streptococcus thermophilus</i>
82	<i>Lachnoanaerobaculum orale</i>		T
83	<i>Lachnoanaerobaculum umeaense</i>	204	<i>Tannerella forsythia</i>
84	<i>Lachnospiraceae</i> [G-2] bacterium HMT 096	205	<i>Tannerella</i> sp. HMT 286
85	<i>Lactobacillus salivarius</i>	206	<i>Tannerella</i> sp. HMT 808


86	Lautropia mirabilis	207	Treponema amylovorum
87	Leptotrichia buccalis	208	Treponema denticola
88	Leptotrichia hofstadii	209	Treponema lecithinolyticum
89	Leptotrichia hongkongensis	210	Treponema maltophilum
90	Leptotrichia shahii	211	Treponema medium
91	Leptotrichia sp. HMT 212	212	Treponema parvum
92	Leptotrichia sp. HMT 215	213	Treponema socranskii
93	Leptotrichia sp. HMT 217	214	Treponema sp. HMT 231
94	Leptotrichia sp. HMT 218	215	Treponema sp. HMT 237
95	Leptotrichia sp. HMT 219	216	Treponema sp. HMT 249
96	Leptotrichia sp. HMT 221	217	Treponema sp. HMT 258
97	Leptotrichia sp. HMT 225	218	Treponema vincentii
98	Leptotrichia sp. HMT 392		U
99	Leptotrichia sp. HMT 417	219	Uncultured
100	Leptotrichia sp. HMT 463		V
101	Leptotrichia sp. HMT 498	220	Veillonella atypica
104	Leptotrichia wadei	221	Veillonella denticariosi
	M	222	Veillonella dispar
105	Megasphaera micronuciformis	223	Veillonella parvula
106	Mycoplasma faucium	224	Veillonella rogosae
	N	225	Veillonella sp. HMT 780
107	Neisseria cinerea	226	Veillonella sp. HMT 917
108	Neisseria elongata	227	Veillonellaceae [G-1] bacterium HMT 145
109	Neisseria flava	228	Veillonellaceae [G-1] bacterium HMT 155
110	Neisseria flavescens		
	O		
114	Oribacterium asaccharolyticum		

**GRAPH 1-A: BAR GRAPH DEMONSTRATING DISTRIBUTION OF BACTERIAL PHYLUM IN HEALTH AND IMPLANT**



**GRAPH 1-B: BAR GRAPH DEMONSTRATING DISTRIBUTION OF BACTERIAL GENUS IN HEALTH AND IMPLANT**







**GRAPH 1-C: BAR GRAPH DEMONSTRATING DISTRIBUTION OF BACTERIAL SPECIES IN HEALTH AND IMPLANT**




**GRAPH 2-A: TOP 5 PHYLUM IN HEALTH**



**GRAPH 2-B: TOP 5 PHYLA IMPLANT**



**GRAPH 3-A: TOP 5 GENERA IN HEALTH**



**GRAPH 3-B: TOP 5 GENERA IN IMPLANT**





TABLE 3-C: PHYLOGENETIC TREE AT GENUS LEVEL





## *Discussion*

---

## DISCUSSION

The simple presence of oral microbiota in the mouth inhibits colonisation by pathogens, the phenomenon of colonisation resistance. Because all surfaces of the mouth are colonised by commensals there are few binding sites available for pathogens <sup>121</sup>.

The human salivary microbiome may be a factor that plays a role in diseases of the oral cavity and interacts with microbiomes from other parts of the human body (in particular, the intestinal tract), but only little is known about normal variation in the salivary microbiome. The main reason for analyzing the human salivary microbiome is that since saliva is increasingly preferred for sampling in humans, as a source of DNA for epidemiologic and population genetic studies <sup>19</sup>, it would be useful to identify bacterial taxa in saliva which in turn will be able to provide us with insights into human population structure and migrations.

Bacteria that normally reside in the oral cavity (i.e. the indigenous microbiota) can select from different ecosystems for their habitat. Most pathogenic species (with the exception of spirochetes who limit themselves to the pocket) are able to colonise all five niches of the oral cavity <sup>28</sup>. Some periodontopathogens (*F. nucleatum* and *P. intermedia*) are involved in the aetiology of tonsillitis, while others can even colonise the maxillary sinus. Since most pathogens are found in more than one niche, it is reasonable to assume that transmission occurs between these intra-oral niches (*called*



*translocation*) occurs. The existence of such a translocation was illustrated by **Quirynen et al. in 1999**<sup>79</sup>. Such a translocation is made possible only in the presence of a fluid medium such as saliva.

An inflammation that is of peri-implant origin usually represents the presence of a disease after the placement of a dental implant, which affects both the surrounding hard and soft tissue. Due to the high prevalence of peri-implantitis, routine check-ups and evaluation along with elimination of risk factors (e.g. smoking, systemic diseases and specific continuous periodontitis) are recommended maintenance measures<sup>57</sup>. In addition to the different aspects involved in the process of osseointegration, the type and structure of the implant surface are also of importance<sup>27, 65</sup>. For the treatment of peri-implant disease conditions various conservative and surgical approaches can be utilised. This however recognises that treatment of peri-implantitis does not yield the same optimal results in terms of surgical and non-surgical management of periodontal diseases.

The need for biomarker based assessment of peri-implant sites that are likely to undergo destruction is therefore great.

There are hundreds of uncultivated bacterial species still remaining in the human oral cavity, and thus the role of the oral microbiome in health and disease is not yet fully understood. Previous studies which were conducted solely focused on the pathogens of teeth and implant and to explore the influence of implants on the oral microbiome.<sup>2</sup>

A number of in vitro studies have been published documenting the bacterial leakage along the interface at implant-abutment assemblies. Essentially, these indicated a bidirectional flux of fluids and bacteria via the microgap<sup>117</sup>, which occurred within days following placement, at all implant types and implant-abutment configurations<sup>98</sup>. The phenomenon was reduced when the closing torque of the abutment screw was increased.

In addition, more bacterial penetration was found along the transversal screw of screw-retained assemblies when compared with the microgap separating the implant from the abutment.

In a study conducted by **Lee KH et al**<sup>58</sup> focused on exploring possible oral sources of species colonizing the oral cavity in patients with newly placed implants by comparing the pre and post implantation microbiota. Most of the microbial species were found on teeth and on the dorsum of the tongue before the implants were actually placed, indicating that there is an impact of the pre-implant microbiota on microbial colonization of dental implants. This impact of the pre-implantation microbiota was also observed in three subjects that were colonized at relatively lower levels both before and after implant placement. The similarity of the bacterial samples obtained from the patients on the same visit from around the teeth and implants in partially dentate subjects indicate that the teeth are a likely source of implant species has previously been described (**Shulman & Shepard 1989, Quirynen & Listgarten 1990, Meffert 1993, Mombelli et al. 1995**)<sup>72</sup>. It may also reflect a

similarity in chronology and quantity of plaque formation following the anti-microbial regimen associated with implant surgery (**Eke et al. 1995**).

Previous researchers have established that NGS technology is an open-ended technique recognised for its high-throughput genomic analysis approach and its ability to quantify abundance of bacterial species. Its use has been applied in this study for sequencing the microbiome of unstimulated saliva samples from patients with implants placed in their oral cavity and periodontally healthy subjects. Illumina sequencing, being an advent of NGS technology has been utilised in this study as it provides more sequences per run, analyses a larger sample size, has a better assessment of the microbiome diversity, includes more bar-coded time points and samples, generates and sequences short 16S rRNA amplicons to determine even low abundance mtaxa.

The V3-V4 region of 16S rRNA were used in this study because though V4 region provides a full overlap of two reads and reduces the noise in sequencing data thereby preventing OTU inflation but there is only less information contained within V4 region owing to its length (~255 base pairs) so a longer fragment such as the V3 which spans multiple hypervariable regions was also selected and is more suitable for distinguishing all bacterial species to genus level.

Subjects were periodontally evaluated and allocated into two groups as healthy controls (ten subjects) and patients with implants placed in their oral

cavity, six months after the loading of the prostheses (ten subjects). Sterile containers with measurements were used to collect the unstimulated whole saliva samples based on the reliability as observed in earlier literature. In the experimental workflow, all reactions were carried out with water and plastic materials guaranteed as DNA-free to avoid contamination.

The purpose of the study was to understand the salivary microbiome in an implant environment and since only a few studies have been conducted (**Cássio do Nascimento et al**) keeping this aim in mind, the study was taken up by our department.

A vast diversity of salivary microflora and inter-individual variations among all samples were observed in our study. A total of 10 phyla, 53 genera and 187 species were observed in healthy sites; and 11 phyla, 60 genera and 228 species were found in the implant sites.

When the salivary microbiome was analysed at phylum level, with the top five phyla in healthy sites being phylum *Firmicutes* with the highest abundance of (28.63%) followed by *Bacteroidetes* (28.43%), *Fusobacteria* (15.9%), *Proteobacteria* (13.32%) and *Actinobacter* (6.56%), the results of our study fall in line with these earlier studies conducted by **Egija Zaura**

*Streptococcus*, *Selenomonas*, *Pectinatus* and *Cohnella* also belong to the phylum *Firmicutes*. Our study also reports a higher abundance of *Proteobacteria* and *Fusobacteria*. *Proteobacteria* phylum comprises of species such as *Campylobacter*, *Kingella*, *Eikenella* and *Neisseria* and *Fusobacteria*

phylum comprises genera *Fusobacterium* and *Leptotrichia*; all of which are known to be early colonisers.

In implant sites, the top five phyla are phylum Firmicutes (31.7%) which has shown the highest abundance of 31.7% followed by Bacteroidetes (26.1%), Fusobacteria (15.49%), Proteobacteria 9.23 % and TM7 (7.33%). In a study conducted by **Cássio do Nascimento et al** which was similar to the our study, it was observed that the most prevalent species found in patients with titanium implants were the Gram-negative bacteria belonging mainly to the phylum *Proteobacteria*, which includes the *Neisseriaceae* and *Campylobacteraceae* families, followed by the phyla *Firmicutes* and *Actinobacteria* and *Bacteroidetes*, this correlates with the results of our study. The only phyla that was absent in healthy samples was *Synergistetes*. Studies were conducted by **Sonia R. Vartoukian** in which *Synergistetes* was cultured to obtain a new genus *Fretibacterium* and the new species *Fretibacterium fastidiosum* in 2009<sup>120</sup>. The cells are asaccharolytic and major amounts of acetic acid and moderate amounts of propionic acid are produced as end products of metabolism in peptone-yeast extract-glucose broth supplemented with a filtered cell sonicate of *Fusobacterium nucleatum*.

At genus level, *Prevotella* was the predominant genus among both the healthy sites (12.82%) and implant sites (12.4%) this correlates with the study conducted by **Daniel Blestorn**. The genus *Neisseria* and *Eikenella* were found to be more abundant in the study conducted by **Cássio do Nascimento et al**. Following this is *Leptotrichia* with values of 9.14% and 9.23%

respectively, the next four genera in healthy sites are *Fusobacterium* (6.75%), *Veillonella* (6.26%), *Porphyromonas* (5.16%) and *Nisseria* (4.97%) and in implant sites are *Saccharibacteria* (6.61%), *Fusobacterium* (6.15%), *Porphyromonas* (5.52%) and *Veillonella* (5.52%). This correlates with the results from previous studies conducted by **Sonia R. Vartoukian**.

The genera found in healthy samples that were not in implant samples were: *Adlercreutzia*, *Anaerococcus*, *Bergeyella*, *Clostridiales*, *Johnsonella*, *Odoribacter*, *Johnsonella*, *Pyramidobacter*, *Scardovia*, *Sporanaerobacter*. The genera found in patient with implants that were not present in healthy patients are: *Absconditabacteria*, *Anaerovorax*, *Eggerthella*, *Erwinia*, *Novosphingobium*, *Slackia*.

A total of 187 species were identified in health and 228 species identified in implants. Among the top 15 species found in both healthy and implant patients, *Porphyromonas pasteri* showed the highest abundance of 2.68% in health and 2.81% in implant this was followed by *Fusobacterium nucleum subsp. vincentii* this correlated with the results based on a comparative study conducted between zirconia and titanium implants, in which the titanium implants showed the presence of *Fusobacterium nucleum* species more predominantly.

At species level, the top 15 species in healthy samples were *Porphyromonas pasteri* (2.68%) *Fusobacterium nucleum subsp. Vincentii* (2.18%), *Veillonella parvula* (1.59%) *Capnocytophaga sputigena* (1.49%), *Alloprevotella sp. HMT 473* (1.19%) *Prevotella veroralis* (1.19%),

*Fusobacterium periodonticum* (1.09%) *Bergeyella* sp. HMT 322 (0.99%), *Campylobacter concisus* (0.99%) *Fusobacterium* sp. HMT 370 (0.99%), *Gemella haemolysins* (0.99%), *Gemella morbillorum* (0.99%), *Gemella sanguine*( 0.99%), *Granulicatella adiacens*( 0.99%), *Haemophilus parainfluenzae* (0.99%)

The top 15 bacterial species found in implants related sites were: *Porphyromonas pasteri* (2.8%), *Fusobacterium nucleatum subsp. Vincentii* (1.99%), *Capnocytophaga sputigena* (1.35%) *Veillonella parvula* (1.35%) *Capnocytophaga leadbetteri* (1.17%), *Capnocytophaga granulosa* (1.086%) *Megasphaera micronuciformis* (0.99%), *Catonella morbi* (0.90%) *Fusobacterium periodonticum* (0.90%), *Gemella morbillorum* (0.90%), *Granulicatella adiacens* (0.90%), *Haemophilus parainfluenzae* (0.90%) *Leptotrichia hofstadii* (0.90%), *Oribacterium parvum* (0.90%), *Prevotella* sp. HMT 313 (0.90%). These results were in contrast to the results obtained in the study conducted by **Jan Cosyn et al**, in which it was found that the species with highest abundance in implants was for *Fusobacterium periodonticum* followed by *Fusobacterium nucleatum* sp. *Nucleatum*.

Species found exclusively in healthy samples: *Acinetobacter johnsonii* *Actinomyces* sp. HMT 175, *Aggregatibacter paraphrophilus*, *Aggregatibacter* sp. HMT 513, *Bifidobacterium animalis*, *Capnocytophaga* sp HMT 878, *Eggerthella lenta*, *Enterobacter cancerogenus*, *Enterococcus casseliflavus*, *Enterococcus saccharolyticus*, *Filifactor alocis*, *Gemella bergeri*,

*Haemophilus influenzae* *Kingella* sp. HMT 932 , *Klebsiella aerogenes*,  
*Lactobacillus crispatus*, *Novosphingobium panipatense*,  
*Peptostreptococcaceae* [XI][G-5] bacterium HMT 493, *Prevotella* sp. HMT  
 304, *Slackia exigua*

Apart from this species found exclusively in implant related samples  
 were: *Actinomyces oris* ,*Actinomyces* sp. HMT 169 ,*Anaerococcus octavius*,  
*Bacteroides heparinolyticus*,*Bacteroidetes* [G-3] bacterium HMT 280,  
*Bacteroidetes* [G-3] bacterium HMT 436, *Bacteroidetes* [G-5] bacterium  
 HMT 505 , *Bacteroidetes* [G-6] bacterium HMT 516,*Bulleidia extructa*,  
*Butyrivibrio* sp. HMT 080, *Capnocytophaga* sp. HMT 324, *Capnocytophaga*  
 sp. HMT 338, *Clostridiales* [F-1][G-1] bacterium HMT 093, *Dialister*  
*pneumosintes*, *Enterococcus faecalis*, *Fretibacterium fastidiosum*,  
*Fretibacterium* sp. HMT 360, etc as stated in the results.

This in turn led to the conclusion that a distinct health-associated  
 salivary microbiome and implant-associated salivary microbiome were  
 identified.

Based on previous studies conducted by Cortelli S<sup>20</sup> it is proven that a  
 previous history of periodontitis may imply a condition of peri-implantitis in  
 the future, thereby establishing a relationship between periodontal disease and  
 peri-implant conditions.



**Limitations of the study:**

Due to the presence of vast numbers of uncultured species that have not been accounted for by the HOMI database, there are still a lot of microorganisms that we are unaware of and these microorganisms may be one of the key pathogens that are involved in the pathogenesis of disease.

## *Summary and Conclusion*

---

---

## SUMMARY AND CONCLUSION

This study characterized salivary microbiome in patients with dental endosseous implants placed in their oral cavity (6 months post loading). Ten unstimulated whole salivary samples obtained from patients with implants placed in their oral cavity (6 months post loading) and ten samples from periodontally healthy were collected and microbiome characterization was done using NGS technology using Illumina sequencing.

A wide array of microbes were identified in health and implant belonging to a complex community structure comprising 10 phyla, 53 genus, 187 species in healthy subjects and 11 phyla, 60 genus and 228 species in the implant patients.

Both the health and implant samples showed a higher abundance value for *Fusobacterium nucleatum* and *Veillonella* species, which are the initial colonisers. The phyla *Firmicutes* is found to be the highest in both implant and healthy samples and the Genera *Prevotella* was found have the highest abundance in both implant and healthy samples. At the species level *Porphyromonas pasteri* was observed to have the highest abundance in both implant and healthy samples.

A distinct salivary microbiome is found in implant samples when compared to healthy samples. Further studies need to be done to identify the role of these bacteria in periodontal health and implant patients.



# *Bibliography*

---

**REFERENCE:**

1. **Albrektsson, T. and Johansson, C.,** 2001. Osteoinduction, osteoconduction and osseointegration. *European spine journal*, 10(2), pp.S96-S101.
2. **Ata-Ali, J., Flichy-Fernández, A.J., Alegre-Domingo, T., Candel-Marti, M.E., Peñarrocha, D., Balaguer-Martinez, J.F. and Peñarrocha, M.A.,** 2011. Analysis of the peri-implant microbiota in 90 dental implants and its relationship to crevicular fluid volume. *Med Oral Patol Oral Cir Bucal*, 16(7), pp.e944-7.
3. **Ahrens, M., Ankenbauer, T., Schroder, D., Hollnagel, A., Mayer, H. & Gross, G.** (1993) Expression of human bone morphogenetic proteins-2 or -4 in murine mesenchymal progenitor C3H10T1/2 cells induces differentiation into distinct mesenchymal cell lineages. *DNA and Cell Biology* 12: 871–880.
4. **American Academy of Periodontology.** (2013) Peri-implant mucositis and peri-implantitis: a current understanding of their diagnoses and clinical implications. *Journal of Periodontology* 84: 436–443
5. **Arikan, F., Buduneli, N. & Lappin, D.F.** (2011) Ctelopeptide pyridinoline crosslinks of type I collagen, soluble RANKL, and osteoprotegerin levels in crevicular fluid of dental implants with

- periimplantitis: a case-control study. *The International Journal of Oral & Maxillofacial Implants* 26: 282–289.
6. **Baron, R. and Saffar, J.L.**, 1978. A quantitative study of bone remodeling during experimental periodontal disease in the golden hamster. *Journal of periodontal research*, 13(4), pp.309-315.
  7. **Belstrøm, D., Paster, B.J., Fiehn, N.E., Bardow, A. and Holmstrup, P.**, 2016. Salivl fingerprints of established oral disease revealed by the Human Oral Microbe Identification using Next Generation Sequencing
  8. **Bennell, K. L., Malcolm, S. A., Brukner, P. D., Green, R. M., Hopper, J. L., Wark, J. D. & Ebeling, P. R.** (1998) A 12-month prospective study of the relationship between stress fractures and bone turnover in athletes. *Calcified Tissue International* 63, 80–85.
  9. **Bosman, F.T. and Stamenkovic, I.**, 2003. Functional structure and composition of the extracellular matrix. *The Journal of Pathology: A Journal of the Pathological Society of Great Britain and Ireland*, 200(4), pp.423-428.
  10. **Booth, V., Young, S., Cruchley, A., Taichman, N.S. & Paleolog, E.** (1998) Vascular endothelial growth factor in human periodontal disease. *Journal of Periodontal Research* 33: 491–499.

11. **Bye FI, Caffesse RG, Nasjleti CE.** The effect of different plaque control modalities on the keratinizing potential of the sulcular epithelium in monkeys. *J Periodontol* 1980; 51: 632–641.
12. **Blair HC, Robinson LJ, Zaidi M.** Osteoclast signalling pathways. *Biochem Biophys Res Commun* 2005;328:728–38.
13. **Caffesse RG, Kornman KS, Nasjleti CE.** The effect of intensive antibacterial therapy on the sulcular environment in monkeys. Part II. Inflammation, mitotic activity and keratinization of the sulcular epithelium. *J Periodontol* 1980; 51: 155–161.
14. **Carcuac, O., Abrahamsson, I., Albouy, J.P., Linder, E., Larsson, L. & Berglundh, T.** (2013) Experimental periodontitis and peri-implantitis in dogs. *Clinical Oral Implants Research* 24: 363–371.
15. **Chen XT, Tan JY, Lei LH and Chen LL:** Cytokine levels in plasma and gingival crevicular fluid in chronic periodontitis. *Am J Dent* 28: 9-12, 2015.
16. **Chukhlovina AB, Solovyova AM, Matelo SK, Kobiyasova IV, Morosova EB, Hokhlacheva AV, et al.** Bacterial markers of periodontal diseases and their practical significance in dentistry. *Bull Exp Biol Med.* 2007;144:546-50.
17. **Colombo AP, Boches SK, Cotton SL, Goodson JM, Kent R, Haffajee AD, et al.** Comparisons of subgingival microbial profiles of



refractory periodontitis, severe periodontitis, and periodontal health using the human oral microbe identification microarray. *J Periodontol* 2009; 80: 142132.

18. **Chukhlovin AB, Solovyova AM, Matelo SK, Kobiyasova IV, Morosova EB, Hokhlacheva AV, et al.** Bacterial markers of periodontal diseases and their practical significance in dentistry. *Bull Exp Biol Med.* 2007;144:546-50.
19. **Ivan Nasidze, Jing Li, Dominique Quinque, Kun Tang, and Mark Stoneking** Global diversity in the human salivary microbiome  
Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 20031, China; Max Planck Institute for Evolutionary Anthropology, D-04103 Leipzig, Germany
20. **Cortelli, S.C., Cortelli, J.R., Romeiro, R.L., Costa, F.O., Aquino, D.R., Orzechowski, P.R., Araújo, V.C. and Duarte, P.M.,** 2013. Frequency of periodontal pathogens in equivalent peri-implant and periodontal clinical statuses. *Archives of oral biology*, 58(1), pp.67-74.
21. **Clark EA, Brugge JS.** Integrins and signal transduction pathways: the road taken. *Science* 1995;268:233–9.

22. **Dahle'n G, Leonhardt A°** . A new checkerboard panel for testing bacterial markers in periodontal disease. *Oral Microbiol Immunol* 2006; 21: 611.
23. **Dave S, Batista ELJ, Van Dyke TE**. Cardiovascular disease and periodontal diseases: commonality and causation. *Compend Contin Educ Dent* 2005; 25: 26–37.
24. **Delima SL, McBride RK, Preshaw PM, Heasman PA, Kumar PS**. Response of subgingival bacteria to smoking cessation. *J Clin Microbiol*. 2010;48:2344-9.
25. Devine, D.A., Marsh, P.D. and Meade, J., 2015. Modulation of host responses by oral commensal bacteria. *Journal of oral microbiology*, 7(1), p.26941.
26. **.Dent, D., Olson, J.W., Farish, S.E., Bellome, J., Casino, A.J., Morris, H.F. & Ochi, S.** (1997) The influence of preoperative antibiotics on success of endosseous implants up to and including stage II surgery: A study of 2,641 implants. *Journal of Oral and Maxillofacial Surgery* 55: 19–24.
27. **Esposito, M., Hirsch, J.-M., Lekholm, U. & Thompsen, P.** (1998) Biological factors contributing to failures of osseointegrated oral implants. *European Journal of Oral Sciences* 106: 527–551.

28. **Faot, F., Nascimento, G.G., Bielemann, A.M., Campão, T.D., Leite, F.R. and Quirynen, M.,** 2015. Can peri-implant crevicular fluid assist in the diagnosis of peri-implantitis? A systematic review and meta-analysis. *Journal of periodontology*, 86(5), pp.631-645.
29. **Feng JQ, Huang H, Lu Y, Ye L, Xie Y, Tsutsui TW, Kunieda T, Castranio T, Scott G, Bonewald LB, Mishina Y.** The dentin matrix protein 1 (dmp1) is specifically expressed in mineralized, but not soft tissues during development. *J Dent Res* 2003; 82: 776–780.
30. **Fransson, C., Lekholm, U., Jemt, T. and Berglundh, T.,** 2005. Prevalence of subjects with progressive bone loss at implants. *Clinical oral implants research*, 16(4), pp.440-446.
31. **Feng X.** RANKing intracellular signaling in osteoclasts. *IUBMB Life* 2005;57:389–95.
32. **Garlet GP:** Destructive and protective roles of cytokines in periodontitis: A re-appraisal from host defense and tissue destruction viewpoints. *J Dent Res* 89: 1349-1363, 2010
33. **"Germ Theory".** *jrank.org*. Archived from the original on 31 January 2016. Retrieved 1 January 2016.
34. **Gianoulis TA, Raes J, Patel PV, Bjornson R, Korbel JO, et al.** (2009) Quantifying environmental adaptation of metabolic pathways in metagenomics. *Proc Natl Acad Sci U S A* 106: 1374–1379.

35. **Giannobile, W.V., Lynch, S.E., Denmark, R.G., Paquette, D.W., Fiorellini, J.P. and Williams, R.C.,** 1995. Crevicular fluid osteocalcin and pyridinoline cross-linked carboxyterminal telopeptide of type I collagen (ICTP) as markers of rapid bone turnover in periodontitis: A pilot study in beagle dogs. *Journal of clinical periodontology*, 22(12), pp.903-910.
36. **Giannobile, W.V., Beikler, T., Kinney, J.S., Ramseier, C.A., Morelli, T. and Wong, D.T.,** 2009. Saliva as a diagnostic tool for periodontal disease: current state and future directions. *Periodontology 2000*, 50(1), pp.52-64.
37. **Gmur, R., Strub, J. R. & Guggenheim, B.** (1989) Prevalence of *Bacteroides forsythus* and *Bacteroides gingivalis* in subgingival plaque of prosthodontically treated patients on short recall. *Journal of Periodontal Research* 24, 113-120.
38. **Gottlander M** (1994) On hard-tissue reactions to hydroxyapatite-coated titanium implants. PhD thesis, Dept of Biomaterials/Handicap Research, University of Göteborg, Sweden, pp 1–192 20
39. **Hasan, N.A., Young, B.A., Minard-Smith, A.T., Saeed, K., Li, H., Heizer, E.M., McMillan, N.J., Isom, R., Abdullah, A.S., Bornman, D.M. and Faith, S.A.,** 2014. Microbial community

profiling of human saliva using shotgun metagenomic sequencing. *PLoS One*, 9(5), p.e97699.

40. **Hauschka, P.V. and Wians, F.H.**, 1989. Osteocalcin-hydroxyapatite interaction in the extracellular organic matrix of bone. *The Anatomical Record*, 224(2), pp.180-188.

41. **Heuer, W., Stiesch, M. and Abraham, W.R.**, 2011. Microbial diversity of supra-and subgingival biofilms on freshly colonized titanium implant abutments in the human mouth. *European journal of clinical microbiology & infectious diseases*, 30(2), pp.193-200.

42. **Heuer, W., Elter, C., Demling, A., Neumann, A., Suerbaum, S., Hannig, M., Heidenblut, T., Bach, F.W. and Stiesch-Scholz, M.**, 2007. Analysis of early biofilm formation on oral implants in man. *Journal of oral rehabilitation*, 34(5), pp.377-382.

43. **Hultin, M., Gustafsson, A., Hallström, H., Johansson, L.Å., Ekfeldt, A. and Klinge, B.**, 2002. Microbiological findings and host response in patients with peri-implantitis. *Clinical oral implants research*, 13(4), pp.349-358.

44. **Howe AK, Juliano RL.** Distinct mechanisms mediate the initial and sustained phases of integrin-mediated activation of the Raf/MEK/mitogen-activated protein kinase cascade. *J Biol Chem* 1998;273:27268–74.

45. **Huang, Y.H., Polimeni, G., Qahash, M. and Wikesjö, U.M.**, 2008. Bone morphogenetic proteins and osseointegration: current knowledge–future possibilities. *Periodontology 2000*, 47(1), pp.206-223.
46. **Huggins CB** (1931) The formation of bone under the influence of epithelium of the urinary tract. *Arch Surg* 22:377– 386 21.
47. **Iozzo RV**. Matrix proteoglycans: from molecular design to cellular function. *Annu Rev Biochem* 1998; 67: 609–652.
48. **Jarry, C.R., Martinez, E.F., Peruzzo, D.C., Carregaro, V., Sacramento, L.A., Araújo, V.C., Weitzmann, M.N. and Napimoga, M.H.**, 2016. Expression of SOFAT by T-and B-lineage cells may contribute to bone loss. *Molecular medicine reports*, 13(5), pp.4252-4258.
49. **John M. Last**, ed. (2007), "'miasma theory'", *A Dictionary of Public Health*, Westminster College, Pennsylvania: Oxford University Press
50. **Johansson CB**(1991) On tissue reactions to metal implants. PhD thesis, Dept of Biomaterials/Handicap Research, University of Göteborg, Sweden, pp 1–203 22.
51. **Johansson C, Albrektsson T, Roos A** (1992) A biomechanical and histomorphometric comparison between different types of bone

implants evaluated in a rabbit model. Eur J Exp Musculoskel Research 1:51–61 23.

52. **Johansson C, Han CH, Wennerberg A, Albrektsson T** (1998) A quantitative comparison of machined commercially pure titanium and titanium-aluminumvanadium implants in rabbit bone. Int J Oral Maxillofac Implants 13:315–321 24.

53. **Korhonen LK, Väänänen K** (1992) Bone inductive molecules and enhancement of repair and regeneration. In: Hall BK (ed) Fracture repair and regeneration, vol 5. CRC, Boca Raton, pp 209–232.

54. **Kresse H, Schonherr E**. Proteoglycans of the extracellular matrix and growth control. J Cell Physiol 2001; 189: 266–274.

55. **Khammissa RAG, Feller L, Meyerov R, Lemmer J**: Peri-implant mucositis and peri-implantitis: clinical and histopathological characteristics and treatment. SADJ 2012, 67(122):124–126.

56. **Koka, S., Razzoog, M., Bloem, T.J. & Syed, S.** (1993) Microbial colonization of dental implants in partially edentulous patients. Journal of Prosthetic Dentistry 70: 141–144.

57. **Koyanagi, T., Sakamoto, M., Takeuchi, Y., Ohkuma, M. and Izumi, Y.,** 2010. Analysis of microbiota associated with peri-implantitis using 16S rRNA gene clone library. *Journal of oral microbiology*, 2(1), p.5104.

58. **Lee, K.H., Tanner, A.C.R., Maiden, M.F.J. and Weber, H.P.,** 1999. Pre-and post-implantation microbiota of the tongue, teeth, and newly-placed implants. *Journal of Clinical Periodontology*, 26(12), pp.822-832.
59. **Lozupone C, Knight R** (2005) UniFrac: a new phylogenetic method for comparing microbial communities. *Appl Environ Microbiol* 71: 8228–8235
60. **Lu, X., Ito, Y., Atsawasuwan, P., Dangaria, S., Yan, X., Wu, T., Evans, C.A. and Luan, X.,** 2013. Ameloblastin modulates osteoclastogenesis through the integrin/ERK pathway. *Bone*, 54(1), pp.157-168.
61. **Livak KJ and Schmittgen TD:** Analysis of relative gene expression data using real-time quantitative PCR and the 2<sup>-</sup>(Delta Delta C(T)) Method. *Methods* 25: 402-408, 2001.
62. **Lozupone CA, Hamady M, Kelley ST, Knight R** (2007). Quantitative and qualitative  $\beta$  diversity measures lead to different insights into factors that structure microbial communities. *Appl Environ Microbiol* 73:1576- 1585
63. **Lander AD, Selleck SB.** The elusive functions of proteoglycans: in vivo veritas. *J Cell Biol* 2000; 148: 227–232.



64. **Lang, N.P., Karring, T. & Meredith, N.** (2002) Implant therapy summary: 4th European Workshop on Periodontology. *Journal of Clinical Periodontology* 29 (Suppl. 3): 232–234.
65. **Leonardt, Å., Adolfsson, B., Lekholm, U., Wikström, M. & Dahle'n, G.** (1993) A longitudinal microbiological study on osseointegrated titanium implants in partially edentulous patients. *Clinical Oral Implants Research* 4: 113–120.
66. **Lekholm, U., Gunne, J., Henry, P., Higuchi, K., Linden, U., Bergstrom, C. & van Steenberghe, D.** (1999) Survival of the Brånemark implant in partially edentulous jaws: a 10-year prospective multicenter study. *International Journal of Oral & Maxillofacial Implants* 14: 639–645.
67. **Malamud, D.,** 2011. Saliva as a diagnostic fluid. *Dental Clinics*, 55(1), pp.159-178.
68. **Margulies M et al Nature.** 2005 Sep 15;437(7057):376-80. Epub 2005 Jul 31. Genome sequencing in microfabricated high-density picolitre reactors.
69. **Maruyama, N., Maruyama, F., Takeuchi, Y., Aikawa, C., Izumi, Y. and Nakagawa, I.,** 2014. Intraindividual variation in core microbiota in peri-implantitis and periodontitis. *Scientific reports*, 4, p.6602.

70. **Mecham, R.P.**, 1998. Overview of extracellular matrix. *Current protocols in cell biology*, (1), pp.10-1.
71. **Mitra S, Rupek P, Richter D, Urich T, Gilbert J, Meyer F, et al.** (2011). Functional analysis of metagenomes and metatranscriptomes using SEED and KEGG. *BMC Bioinformatics* 12(Suppl 1):S21.
72. **Mombelli, A., Müller, N. and Cionca, N.**, 2012. The epidemiology of peri-implantitis. *Clinical oral implants research*, 23, pp.67-76.
73. **Morgan, X.C. and Huttenhower, C.**, 2012. Human microbiome analysis. *PLoS computational biology*, 8(12), p.e1002808.
74. **Nanci, A. and Bosshardt, D.D.**, 2006. Structure of periodontal tissues in health and disease. *Periodontology 2000*, 40(1), pp.11-28.
75. **Novince, C.M. and Kirkwood, K.L.**, 2018. Alveolar Bone Homeostasis in Health and Disease. *Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism*, pp.933-940.
76. **Ng, P.Y.B., Donley, M., Hausmann, E., Hutson, A.D., Rossomando, E.F. and Scannapieco, F.A.**, 2007. Candidate salivary biomarkers associated with alveolar bone loss: cross-sectional and in vitro studies. *FEMS Immunology & Medical Microbiology*, 49(2), pp.252-260.
77. **Nanci, A. and Bosshardt, D.D.**, 2006. Structure of periodontal tissues in health and disease. *Periodontology 2000*, 40(1), pp.11-28.

78. **Nishimoto, S.K., and P.A. Price** 1985 The vitamin K-dependent bone protein is accumulated within cultured osteosarcoma cells in the presence of the vitamin K antagonist warfarin. *J. Biol. Chem.*, 260:2832-2836.
79. **Naert, I., Koutsikakis, G., Quirynen, M., Duyck, J., van Steenberghe, D. & Jacobs, R.** (2002) Biologic outcome of implant-supported restorations in the treatment of partial edentulism. Part 2: a longitudinal radiographic study. *Clinical Oral Implants Research* 13: 390–395.
80. **Nomura S, Wills AJ, Edwards DR, Heath JK & Hogan BL** (1988) Developmental expression of *2ar* (osteopontin) and SPARC (osteonectin) RNA as revealed by in situ hybridization. *J Cell Biol* 106: 441–450.
81. **Nishanian P, Aziz N, Chung J, Detels R, Fahey JL** (1998). Oral fluids as an alternative to serum for measurement of markers of immune activation. *Clin Diagn Laboratory Immunol* 5: 507–512.
82. **Offenbacher S** (1996) Periodontal diseases: pathogenesis. *Ann Periodontol* 1: 821–878.
83. **Oringer RJ, Palys MD, Iranmanesh A, Fiorellini JP, Haffajee AD, Socransky SS & Giannobile WV** (1998) C-telopeptide

pyridinoline cross-links (ICTP) and periodontal pathogens associated with endosseous oral implants. *Clin Oral Implants Res* 9: 365–373.

- 84. Oringer RJ, Iacono VJ** Periodontal cosmetic surgery
- 85. Oldberg, A., A. Franzen, and D. Heinegard** 1986 Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence. *Proc. Natl. Acad. Sci. U.S.A.*, 8323819-8823.
- 86. Otawara, Y., and P.A. Price** 1986 Developmental appearance of matrix GLA protein during calcification in the rat. *J. Biol. Chem.*, 261:10828-10832.
- 87. Odber J, Cawood EH, Bancroft J** (1998). Salivary cortisol in women with and without perimenstrual mood changes. *J Psychosom Res* 45: 557–568.
- 88. Pacios, S., Xiao, W., Mattos, M., Lim, J., Tarapore, R.S., Alsadun, S., Yu, B., Wang, C.Y. and Graves, D.T.,** 2015. Osteoblast lineage cells play an essential role in periodontal bone loss through activation of nuclear factor-kappa B. *Scientific reports*, 5, p.16694.
- 89. Popova, C., Dosseva-Panova, V. and Panov, V.,** 2013. Microbiology of periodontal diseases. A review. *Biotechnology & Biotechnological Equipment*, 27(3), pp.3754-3759.

90. **Poser, J.W., and P.A. Price** 1979 A method for decarboxylation of gamma-carboxyglutamic acid in proteins: Properties of the decarboxylated gamma-carboxyglutamic acid from calf bone. *J. Biol. Chem.* 254:431-436.
91. **Prati, A.J., Casati, M.Z., Ribeiro, F.V., Cirano, F.R., Pastore, G.P., Pimentel, S.P. and Casarin, R.C.V.**, 2013. Release of bone markers in immediately loaded and nonloaded dental implants: a randomized clinical trial. *Journal of dental research*, 92(12\_suppl), pp.161S-167S.
92. **Page RC** (1991) The role of inflammatory mediators in the pathogenesis of periodontal disease. *J Periodontal Res* 26: 230–242.
93. **Palomo L, Bissada NF & Liu J** (2005) Periodontal assessment of postmenopausal women receiving risedronate. *Menopause* 12: 685–690.
94. **Philip D. Marsh , Annette Moter ,Deirdre A. Devine**  
First published: 07 December 2010 Dental plaque biofilms: communities, conflict and control
95. **Pozo F, Tenorio A** (1999). Detection and typing of lymphotropic herpesviruses by multiplex polymerase chain reaction. *J Virol Meth* 79: 9–19. Quissell DO (1993).

96. **Price. P. A., Baukol. S, A,** (1980) 1.25(OH)<sub>2</sub>D<sub>3</sub> increases syntethesis of the vitamin K dependent protein by osteosarcoma cells. *Journal of Biological Chemistry* 255.
97. **Reinhardt RA, Masada MP, Kaldahl WB, DuBois LM, Kornman KS, Choi JI, Kalkwarf KL & Allison AC** (1993) Gingival fluid IL-1 and IL-6 levels in refractory periodontitis. *J Clin Periodontol* 20: 225–231.
98. **Reinhardt, R.A., Sanderfer, V.J., Meinberg, T.A., Nummikoski, P., Lee, H.M. and Marx, D.B.,** 2004. Local biochemical markers of bone turnover: relationship to subsequent density of healing alveolar bone defects. *Journal of clinical periodontology*, 31(3), pp.223-228
99. **Richter EJ, Jansen VK, Conrads.** Microbial leakage and marginal fit of the implant-abutment interface. *Int J Oral Maxillofac Implants* 1997; 12:527–540.
100. **Rifas L and Avioli LV:** A novel T cell cytokine stimulates interleukin-6 in human osteoblastic cells. *J Bone Miner Res* 14: 1096-1103, 1999
101. **Reinhardt, R.A., Sanderfer, V.J., Meinberg, T.A., Nummikoski, P., Lee, H.M. and Marx, D.B.,** 2004. Local biochemical markers of bone turnover: relationship to subsequent

density of healing alveolar bone defects. *Journal of clinical periodontology*, 31(3), pp.223-228.

102. **Rao H, Lu G, Kajiya H, Garcia-Palacios V, Kurihara N, Anderson J, et al.** Alpha9beta1: a novel osteoclast integrin that regulates osteoclast formation and function. *J Bone Miner Res* 2006;21:1657–65.
103. **Risteli. J., Elomaa. [., Niemi. S., Novamo. A. & Risteli. L,** (1993) Radioimmunoassay for the pyridinoline cross-linked carboxyterminal telopeptide of type I collagen: a new serum marker of bone collagen degradation. *Chnu-al Chemistry* 39.
104. **Simonis P, Dufour T, Tenenbaum H:** Long-term implant survival and success: a 10-16-year follow-up of non-submerged dental implants. *Clin Oral Implants Res* 2010, 21:772–777
105. **Smeets, R., Henningsen, A., Jung, O., Heiland, M., Hammächer, C. and Stein, J.M.,** 2014. Definition, etiology, prevention and treatment of peri-implantitis—a review. *Head & face medicine*, 10(1), p.34.
106. **Sykaras, N., Triplett, R.G., Nunn, M.E., Iacopino, A.M. and Opperman, L.A.,** 2001. Effect of recombinant human bone morphogenetic protein-2 on bone regeneration and osseointegration

of dental implants. *Clinical oral implants research*, 12(4), pp.339-349.

107. **Socransky, S.S., Haffajee, A.D., Cugini, M.A., Smith, C. and Kent Jr, R.L.**, 1998. Microbial complexes in subgingival plaque. *Journal of clinical periodontology*, 25(2), pp.134-144.

108. **Slovik. M., Gundberg, C M., Neer, R, M, & Lian. J, B**, (1984) Clinical evaluation of bone turnover by serum osteocalcin measurements. *Journal of Clinical Endocrinology and Metabolism* 59, 228-230.

109. **Socransky, S, S., Haffajee, A. D., Goodson. J. M, & Lindhe. J**, (1984) New concepts of destructive periodontal disease. *Journal of Clinical Periodontology* II .

110. **Schmidmaier, G., Wildemann, B., Cromme, F., Kandziora, F., Haas, N.P. and Raschke, M.**, 2002. Bone morphogenetic protein-2 coating of titanium implants increases biomechanical strength and accelerates bone remodeling in fracture treatment: a biomechanical and histological study in rats. *Bone*, 30(6), pp.816-822.

111. **Socransky, S.S., Haffajee, A.D., Cugini, M.A., Smith, C. and Kent Jr, R.L.**, 1998. Microbial complexes in subgingival plaque. *Journal of clinical periodontology*, 25(2), pp.134-144.



112. **Sugahara K, Kitagawa H.** Recent advances in the study of the biosynthesis and functions of sulfated glycosaminoglycans. *Curr Opin Struct Biol* 2000; 10: 518–527.
113. **Subramani K, Jung RE, Molenberg A, Hammerle CH.** Biofilm on dental implant: a review of the literature. *Int J Oral Maxillofac Implants* 2009; 24: 61626.
114. **Sodek, J. and Mckee, M.D.,** 2000. Molecular and cellular biology of alveolar bone. *Periodontology* 2000, 24(1), pp.99-126.
115. **Sbordone L, Barone A, Ciaglia RN, Ramaglia L, Lacono VJ.** Longitudinal study of dental implants in a periodontally compromised population. *J Periodontol* 1999; 70: 13229.
116. **Tumova S, Woods A, Couchman JR.** Heparan sulfate proteoglycans on the cell surface: versatile coordinators of cellular functions. *Int J Biochem Cell Biol* 2000; 32: 269–288.
117. **Talonpoika. J, T & Hamaliinen. M, M.** (1994) Type I collagen carboxyterminal telopeptide in human gingival crevicular fluid in different clinical conditions and after periodontal treatment. *Journal of Clinical Periodontology* 21 320- 326.
118. **Teles RP, Gursky LC, Faveri M, Rosa EA, Teles FR, Feres M, et al.** Relationships between subgingival microbiota and GCF

- biomarkers in generalized aggressive periodontitis. J Clin Periodontol. 2010;37:313-23.
119. **Traversy MC, Birek P.** Fluid and microbial leakage of implant–abutment assembly *in vitro*. J Dent Res 1991;71:754.
120. **Van Winkelhoff, A.J., Goené, R.J., Benschop, C. and Folmer, T.,** 2000. Early colonization of dental implants by putative periodontal pathogens in partially edentulous patients. *Clinical oral implants research*, 11(6), pp.511-520.
121. **Vartoukian SR, Palmer RM, Wade WG.** Diversity and morphology of members of the phylum “Synergistetes” in periodontal health and disease. Appl Environ Microbiol 2009; 75: 377786.
122. **Vollaard EJ, Clasener HA.** Colonization resistance. Antimicrobial Agents and Chemotherapy 1994;38:409–14.
123. **Wang, H.L., Garaicoa-Pazmino, C., Collins, A., Ong, H.S., Chudri, R. and Giannobile, W.V.,** 2016. Protein biomarkers and microbial profiles in peri-implantitis. *Clinical oral implants research*, 27(9), pp.1129-1136.19. Gunday, S., Topcu, A., Guncu, G., Akman, A., Karabulut, E. and Yamalik, N., 2011. Analysis of potential factors affecting peri-Nutton,

124. **Vivian** (1983) "The seeds of disease: an explanation of contagion and infection from the Greeks to the Renaissance," *Medical History*, **27** (1): 1–34 ; see p. 10. Available at: U.S. National Library of Medicine, National Institutes of Healthsulcus fluid (PISF) volume. *Clin Dent Res*, **35**, pp.12-24.
125. **Wennstroöm, J. & Palmer, R.** (1999) Consensus report of session 3: clinical trials. In: Lang, N., Karring, T. & Lindhe, J., eds. Proceedings of the 3rd European Workshop on Periodontology. Implant Dentistry, 255–259.
126. **Wozney J. M.** Bone morphogenetic proteins and their gene expression. Noda M., ed. Cellular and Molecular Biology of Bone. Tokyo: Academic; 131–167; 1993.
127. **Wozney J. M., Rosen V., Celeste A. J , Mitsock L. M., Whitters M. J., Kriz R. W., Hewick R. M., and Wang E. A.** Novel regulators of bone formation: molecular clones and activities. *Science* **242**:1528–1534; 1988.
128. **Wilson V:** An insight into peri-implantitis: a systematic literature review. *Prim Dent J* 2013, **2**:69–73.
129. **Yamamoto, M., Tabata,Y. & Ikada,Y.** (1998) Ectopic bone formation induced by biodegradable hydrogels incorporating bone

morphogenetic protein. Journal of Biomaterials Science, Polymer Edition 9: 439–458.


130. **Yasko, A.W., Lane, J.M., Fellingner, E.J., Rosen, V., Wozney, J.M. & Wang, E.A.** (1992) The healing of segmental bone defects, induced by recombinant human bone morphogenetic protein (rhBMP-2). A radiographic, histological, and biomechanical study in rats [published erratum appears in J Bone Joint Surg Am 1992 Aug;74(7):1111]. Journal of Bone and Joint Surgery. American Volume 74: 659–670.
131. **Yasumura. S., Aloia. J., Yeh. J., Vaswani. A. N., Ytien. K., LoMonte. A- F. Ellis. K. J., & Gundberg. C. M.** (1987) Serum osteocalcin and total body calcium in normal, pre- and post menopausal women and post-menopausal osteoporotic patients. Journal of Clinical Endocrinology and Metabolism 64.
132. **Yamaguchi Y.** Leticans: organisers of the brain extracellular matrix. CMLS Cell Mol Life Sci 2000; 57: 276–289.
133. **Yoshida K., Bessho K., Fujimura K., Ogawa Y., Tani Y., and Iizuka T.** Osteoinduction capability of recombinant human bone morphogenetic protein-2 in intramuscular and subcutaneous sites: an experimental study. J Craniomaxillofac Surg 26:112–115; 1998.

134. **Zapf J., Hauri C., Waldvogel M., and Froesch E. R.** Acute metabolic effects and half-lives of intravenously administered insulinlike growth factors I and II in normal and hypophysectomized rats. *J Clin Invest* 77:1768–1775; 1986.
135. **Zegzula H. D., Buck D. C., Brekke J., Wozney J. M., and Hollinger J. O.** Bone formation with use of rhBMP-2 (recombinant human bone morphogenetic protein-2). *J Bone Jt Surg [Am]* 79:1778–1790; 1997.
136. **Zaura, E.,** 2012. Next-generation sequencing approaches to understanding the oral microbiome. *Advances in dental research*, 24(2), pp.81-85.
137. **Zaura, E.,** Role of microbial biofilms in the maintenance of oral health and in the development of dental caries and periodontal diseases

## *Annexures*

---

**ANNEXURE I- IRB REPORT**

 **RAGAS DENTAL COLLEGE & HOSPITAL**  
(Unit of Ragas Educational Society)  
Recognized by the Dental Council of India, New Delhi  
Affiliated to The Tamilnadu Dr. M.G.R. Medical University, Chennai  
2/102, East Coast Road, Uthandi, Chennai - 600 119, INDIA.  
Tele : (044) 24530002, 24530003 - 06. Principal (Dir) 24530001 Fax : (044) 24530009


---

**TO WHOMSOEVER IT MAY CONCERN**


Date: 30.1.2019  
Place: Chennai.

From  
The Institutional Review Board,  
Ragas Dental College and Hospital,  
Uthandi, Chennai- 600119.

The Dissertation topic titled **"MIROBIOME ANALYSIS OF WHOLE SALIVA USING NEXT GENERATION SEQUENCING TECHNOLOGY IN IMPLANT SUPPORTED PROSTHESIS 6 MONTHS POST LOADING"** Submitted by **DR. ASHA SRIKANTH**, has been approved by the Institutional Review Board of Ragas Dental College & Hospital.

  
**Dr.N.S.Azhagarasan, M.D.S.**  
Member Secretary,  
Institutional Ethical Board,  
Ragas Dental College and Hospital,  
Uthandi, Chennai - 600119

## ANNEXURE II- PLAGIARISM REPORT



### Urkund Analysis Result

Analysed Document: thesis toto.docx (D47313880)  
Submitted: 1/28/2019 8:10:00 AM  
Submitted By: ashasrikanth261092@gmail.com  
Significance: 6 %

#### Sources included in the report:

Review of Literature 2.docx (D47298311)  
ENNET CYNTHIA JOHNS 1.docx (D47312844)  
K.KAVIPRIYA -THESIS.docx (D47312847)  
plagiarism check.docx (D34299138)  
doc for analysis.docx (D34901232)  
plagiarism.docx (D35097967)  
[https://mafiadoc.com/a-positive-correlation-between-occlusal-trauma-and-peri-implant-\\_598cc3401723ddcc692f031b.html](https://mafiadoc.com/a-positive-correlation-between-occlusal-trauma-and-peri-implant-_598cc3401723ddcc692f031b.html)

#### Instances where selected sources appear:

28



**ANNEXURE III**

**CONSENT FORM**

I .....S/o, w/o,  
d/o.....  
aged about .....years, Hindu/Christian/Muslim  
.....residing at  
.....do  
solemnly

And state as follows.

I am the deponent herein; as such I am aware of the facts stated here  
under

I state that I came to Ragas Dental College and Hospital, Chennai for  
my treatment for

.....  
.....

I was examined by Dr..... and I was  
requested to do the following

1. Full mouth Plaque Score
2. Full mouth bleeding score
- 3 Measurement of periodontal pocket depth and clinical attachment loss

I was also informed and explained about the collection of plaque  
during scaling in .....(language) known to me.

I was also informed and explained that the results of the individual test will not be revealed to the public. I give my consent after knowing full consequence of the dissertation/thesis/study and I undertake to cooperate with the doctor for the study.

I also authorise the Doctor to proceed with further treatment or any other suitable alternative method for the study,

I have given voluntary consent to the collection of plaque for approved research.

I am also aware that I am free to withdraw the consent given at any time during the study in writing.

Signature of the patient/Attendant

The patient was explained the procedure by me and has understood the same and with full consent signed in (English/Tamil/Hindi/Telugu?.....) before me

Signature of the Doctor